Podcasts about Inari

This episode covers: Cardiology This Week: A concise summary of recent studies Transcatheter treatment of tricuspid regurgitation Carcinoid heart disease Milestones: MADIT-II Trial Host: Wilfried Mullens Guests: Stephan Baldus, Heidi Connolly and Konstantinos Koskinas Want to watch that episode? Go to: https://esc365.escardio.org/event/2560 Want to watch that extended interview on transcatheter treatment of tricuspid regurgitation, go to: https://esc365.escardio.org/event/2560?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Heidi Connolly, Nicolle Kraenkel and Wilfried Mullens have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Stephan Baldus has declared to have potential conflicts of interest to report: research grant from Abbott, lecture fees from Abbott and Edwards. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Wilfried Mullens Guest: Stephan Baldus Want to watch that extended interview, go to: https://esc365.escardio.org/event/2560?resource=interview Want to watch that entire episode? Go to: https://esc365.escardio.org/event/2560   Disclaimer ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Wilfried Mullens have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Stephan Baldus has declared to have potential conflicts of interest to report: research grant from Abbott, lecture fees from Abbott and Edwards. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Björn ist Diplom-Psychologe und Autor – und er arbeitet seit fast 30 Jahren in einer der ersten Männerberatungsstellen Deutschlands. Ich wollte von ihm wissen, warum Männern der Zugang zu ihren eigenen Gefühlen so schwer fällt und welche Rolle Sozialisation dabei spielt. Wir sprechen über toxische Männlichkeit, Abwehrmechanismen, Hilflosigkeit und Scham, es geht um liebevolles Konfrontieren, die Manosphere und um Zärtlichkeit. WERBEPARTNER & RABATTE: https://linktr.ee/hotelmatze MEIN GAST: https://bjoernsuefke.de/ DINGE: Männerberatungsnetz: https://maennerberatungsnetz.de/soforthilfe/ Hilfetelefon Gewalt an Männern: https://www.maennerhilfetelefon.de/ Alle Bücher von Björn Süfke: https://bit.ly/3SfJOOR https://bit.ly/4aEXnxD https://bit.ly/4edGfjM Film “Zugvögel… Einmal nach Inari” mit Joachim Król: https://bit.ly/4vKaypn Film “Ice Age”: https://bit.ly/43qt9e2 Film “Olivia”: https://bit.ly/4uxcQah Band The XX: https://bit.ly/4fCXxcj Alexander Stößlein & Lukas Hambach - Produktion Lena Rocholl - Redaktion Mit Vergnügen - Vermarktung und Distribution MEIN ZEUG: Hotel Matze live - https://eventim.de/artist/hotel-matze/ Meine Fragensets: beherzt.net/hotel-matze Das Beste des Tages App: https://dasbestedestages.de/ Mein Newsletter: https://matzehielscher.substack.com/ YouTube: https://bit.ly/4fhY2rV TikTok: https://tiktok.com/@matzehielscher Instagram: https://instagram.com/matzehielscherHotel LinkedIn: https://linkedin.com/in/matzehielscher/ Mein Buch: https://bit.ly/3QXmCVc

[powerpresss] My co-host Ken Suzan and I are welcoming you to episode 175 of our podcast IP Fridays! Today's interview guest is Bruce Dearling, patent attorney and partner at Hepworth Browne in the UK, and we talk about how non-technical features must be considered when assessing inventive step of patents at least according to recent decisions of the UK supreme court and the Unified Patent Court. Profile of Bruce Dearling UK Supreme Court Emotional Perception AI Limited UPC Abbot vs Sinocare But before we jump into this interesting interview, I have news for you: On May 20, 2026, the Swiss Federal Council adopted the fully revised Patent Ordinance, which will enter into force on January 1, 2027, together with the revised Patent Act. In the future, the Swiss Federal Institute of Intellectual Property will prepare a mandatory search report for each application; applicants can choose between a partially examined version and a full examination that assesses novelty and inventive step. The full examination costs an additional 300 Swiss francs, and renewal fees will increase by a total of eight percent over the 20-year term. On May 19, 2026, Asus entered into a licensing agreement with the Wi-Fi multimode patent pool managed by Sisvel, thereby ending all ongoing infringement proceedings. Sisvel bundles standard-essential patents in the pool from, among others, Atlantia, ETRI, and Mitsubishi Electric. On May 18, 2026, the UPC Local Chamber in Düsseldorf rejected Align Technology's application for a preliminary injunction against its Chinese competitor Angelalign. Angelalign may continue to sell its clear aligners within the UPC jurisdiction. Our partners Dirk Schulz, Ulrich Storz, and Wanze Zhang, together with Arnold Ruess, successfully represented Angelalign. The U.S. Patent and Trademark Office (USPTO) announced midweek that, since October of last year, it has invalidated or is seeking to invalidate approximately 10,500 trademark applications and registrations in eleven administrative orders. Reasons include forged attorney signatures and the fabrication of non-existent filing requirements. This stems from ongoing abuse of the U.S. trademark system, primarily by non-U.S. applicants, which can lead to conflicts with validly registered trademarks for legitimate businesses. On May 12, 2026, the British Court of Appeal overturned a lower court decision that would have required Nokia to grant interim licenses for video coding patents. The court found that Nokia's license offer to the Taiwanese manufacturers Acer and Asus had already been made on RAND terms. In May, the U.S. Department of Justice (DOJ) filed a brief in the ongoing Corteva v. Inari litigation, expressing antitrust concerns regarding certain patent practices in the field of plant breeding. This marks the first time the agency has actively intervened in a biopharmaceutical patent dispute with implications for seed innovations. Episode 175 of the IP Fridays podcast was a conversation I will not forget quickly. My guest Bruce Dearling, partner at Hepworth Brown in the UK and a patent attorney for 36 years, took a case through every level of the British court system up to the Supreme Court and, in doing so, fundamentally changed patent law for AI inventions in the UK. The case is called Emotional Perception, and its effects reach well beyond British borders. Below I summarize the key points from our conversation. The full episode is available at IP Fridays. A. What Is the Emotional Perception Case About? The underlying invention concerns artificial neural networks. Specifically, it relates to a method of closing what is called the semantic gap at the output of a neural network. That sounds abstract, but the idea is straightforward: a neural network always produces an output that does not fully correspond to what a human would actually expect or feel. Closing that gap brings the system closer to human perception and human expectations. Bruce Dearling drafted this application himself and filed it at the UK Intellectual Property Office (UKIPO). The Office rejected it as excluded subject matter, characterizing it as essentially a computer program as such. The legal basis for that rejection was the Aerotel decision from 2006. The case then went to the High Court, which found in favor of the applicant. The Court of Appeal reversed that decision. Then the UK Supreme Court stepped in and changed everything. B. The Aerotel Test and Its Flaws Since 2006, the Aerotel test had been the standard British method for assessing whether an invention falls within the excluded categories under patent law. It was a four-step approach: construe the claim, identify the actual contribution the invention makes to human knowledge, ask whether that contribution falls solely within excluded subject matter, and finally check whether the contribution is technical in nature. The problem Dearling described in our conversation is that Aerotel reverses the logical order of the analysis. You start with the contribution and only then ask about the exclusions under Article 52 EPC. The UK Supreme Court described Aerotel in its judgment as “unsound law” and overturned it. The EPO’s Technical Boards of Appeal had previously called Aerotel “disingenuous,” which at the time led to a public dispute between the British courts and the Boards. With the Emotional Perception ruling, that conflict has now been resolved in favor of harmonization with the EPO. C. What the UK Supreme Court Decided The Supreme Court made two central findings. First, the exclusion of computer programs “as such” is overcome as soon as a claim includes any piece of hardware. It does not matter whether that is a processor, a memory module, or any other component. The threshold is deliberately low. Dearling described this as the “any hardware” approach, which aligns fully with the EPO’s position following G1/19. Second, and in Dearling’s assessment the more important finding: when assessing inventive step, the invention must be considered as a whole. The Court introduced what it called an “intermediate step,” an analytical stage in which the interactions between all features of a claim are examined before the question of inventive step is addressed. Non-technical features cannot simply be struck out if they contribute to the overall technical effect of the invention. D. Inventive Step: The Intermediate Step This is the heart of the judgment. In EPO practice, Dearling said, it happens regularly that examiners strike through features they consider non-technical and thereby fail to assess the invention’s inventive step correctly. A recent Technical Board of Appeal decision, T 1249/22, already criticized this approach: a claim directed at a technical solution to a problem can be patentable even if the underlying problem is non-technical in nature. Dearling recalled a remark made by a Board of Appeal member at a hearing he attended years ago: “We understand that examining divisions can operate with a degree of mental laziness and that it’s too easy to throw too many things out of the basket when considering the issues of inventive step.” That quote stayed with him because it names a structural problem that the intermediate step now addresses directly. The British method for assessing inventive step is the Pozzoli test, which differs from the EPO’s problem-solution approach. The Supreme Court explicitly retained Pozzoli because the problem-solution approach, in its view, is structurally infected with hindsight reasoning: you already know the invention, you work backwards to formulate an objective technical problem, and then you ask whether it would have been obvious for the skilled person to arrive at precisely that solution. Dearling sees this as a source of unfairness toward genuine inventions. E. Alignment with the Unified Patent Court In April 2025, the Court of Appeal of the Unified Patent Court issued a decision in Abbott v. Sinocare (APP_000000901/2025, judgment of 17 April 2025). Dearling pointed out that this decision uses language and reasoning strikingly similar to the UK Supreme Court’s Emotional Perception ruling of February 2025. That is significant because the UPC is bound neither by UK courts nor by the EPO. The overlap suggests voluntary convergence. Dearling reported a conversation with a person close to the EPO, whom he did not name, who used the word “permissive” to describe the UK Supreme Court’s approach and indicated that the EPO might move toward it. Whether and how quickly that happens remains to be seen. What is clear is that the UPC, as the new European patent court, is setting its own standards, and the question of how to handle non-technical features in inventive step assessment is now being asked at multiple levels simultaneously. F. Implications for the EPO and Practice The EPO is not directly bound by the ruling. It is an administrative body, not a court. Dearling is nonetheless optimistic that change is coming. On one hand, external pressure is building: when the UK Supreme Court and the UPC articulate similar principles, convergence becomes hard to resist. On the other hand, Article 27.1 TRIPS requires all contracting states to make patents available in all fields of technology. Examiners routinely striking non-technical features from AI claims and rejecting them on that basis sits uncomfortably with that obligation. For the underlying application in the Emotional Perception case, the ruling has a pointed consequence. The Supreme Court did not grant the patent itself; it referred the matter back to the UKIPO for reconsideration under the intermediate step. The Office’s subsequent response was, in Dearling’s words, unconvincing. He suspects the Office is attempting to reintroduce the Aerotel test through the back door. As a last resort, he has not excluded a judicial review, a procedure that does not simply challenge the substantive decision but holds the Comptroller General of Patents to account for whether the Office is deliberately circumventing the Supreme Court’s direction on the intermediate step. That is, as Dearling put it, “a nuclear option,” but one he would not rule out if the evidence in the file already suggests the Office is in contempt of court. There is also an international dimension. Singapore’s Intellectual Property Office launched a public consultation shortly after the ruling, asking whether Singapore should adopt the Emotional Perception approach into national law. That is British soft power operating in real time within the Commonwealth. G. Three Takeaways for Patent Practitioners At the end of our conversation I asked Bruce Dearling to distill the most important practical points. His first takeaway: make sure the claim contains hardware. This applies not only to UK and European applications but is simply good drafting hygiene. Without hardware in the claim, the application remains exposed. The second takeaway concerns the description. Anyone filing an AI invention needs to explain clearly which function is achieved by which piece of hardware, circuit, or software. Not as boilerplate, but as a complete technical account that describes the real-world effects. Dearling’s experience is that practitioners who write the claim first and fill in the description afterward run into trouble. The third takeaway emerged from the conversation itself: how the EPO assesses inventive step for AI inventions is not a settled question. It is worth following the development of UPC case law and any shifts in EPO practice closely. Anyone advising on AI patent applications today needs to know these arguments. H. Conclusion The UK Supreme Court’s Emotional Perception ruling is not a British footnote. It has declared the Aerotel test dead, introduced the intermediate step that brings non-technical features back into the inventive step analysis, and set off a convergence movement that is already visible at the UPC and still pending at the EPO. For everyone working in AI patent practice, whether in prosecution, examination, or counseling, this ruling is required reading. Rolf Claessen: Our interview guest on IP Fridays podcast is Bruce Dearling. He has been in the IP field and a patent attorney for 36 years and is partner at Hepworth Brown in the UK. Thank you very much for being on the podcast. Bruce Dearling: My pleasure, Rolf. Thank you for inviting me. Rolf Claessen: All right. We just met at the INTA annual meeting in London. And you talked about the UK Supreme Court case where you were involved. And the core questions were whether non-technical features would be considered when assessing inventive step of patents. Can you briefly summarize this case? Bruce Dearling: It’s a bit more than that. It started — I actually wrote the case. And I prosecuted it through the patent office. The patent office rejected the case for being excluded subject matter. So pretty much the excluded subject matter provisions in the UK are nearly identical. They’re as near as practical to the language of the EPC, so those of the European Patent Office — Article 52.2. But again, they apply as such. The actual technology relates to artificial neural networks. And the invention related to a very clever way of what is termed closing the semantic gap at the output of the neural network. So that means that in a neural network, there is always a discrepancy between the output of the neural network in terms of what it’s telling you you should be thinking essentially, and what reality is. So if you can close the semantic gap, then you align the neural network or the artificial intelligence system to better reflect human knowledge or human reactions and human expectations. So that’s really what the invention is about. There’s no point in going into too much detail with it — that’s the way it is. It’s very clever. So the UKIPO rejected this because they said it was essentially a computer program excluded from patentability as such. And they used a decision which is called Aerotel, which has been around since 2006. And that decision has caused considerable consternation and tension between the EPO Technical Boards of Appeal and the UK courts. Aerotel was described as being essentially disingenuous by the EPO Technical Board of Appeal. And the UK courts pushed back and said, you don’t know what you’re talking about. So that’s where it fell apart. So that’s where they rejected it for essentially being a computer program as such, possibly with a bit of business methods thrown in as well. But let’s leave that for the time being. So the case then went to the High Court and at the High Court, we won. The judge said, actually, it’s not a computer program. Neural networks aren’t computers. They’re not programs themselves. There’s more to them than that. And the invention as claimed is not excluded from patentability as such. The UKIPO obviously weren’t very happy about that because they liked their Aerotel case and so they appealed it. And they appealed it on several grounds, including a new one, which was that it was a mathematical method. The Court of Appeal decided that the UKIPO was right and that we were wrong, so we lost the case. So we then went to the Supreme Court. Well, actually, they denied us an ability to go to the Supreme Court. The court said no appeal. We went — actually, no, I think there is a bigger issue here — because we realized, or I realized at that point, that the work that we were doing was much broader than this. It requires real consideration of what an invention is at a fundamental level. So not only exclusions, but how inventive step is applied. And these issues were built into the case from the very beginning. And they sort of — I wouldn’t say crept up on the court as we went through — but they became more and more prominent to the extent that ultimately, when we made an application to the Supreme Court, the Supreme Court went, yeah, we’ve got some issues here. We want to hear the full arguments on why this is not excluded from patentability, why Aerotel is potentially bad and how we more or less try to align ourselves with the European Patent Office. So that’s essentially what happened. And the Supreme Court hearing was last July. It took them the thick end of eight months to come out with a decision, which was issued in early February, at which point the entire legal landscape in the UK changed because they said we were right. The Patent Office doesn’t know what they’re talking about. Aerotel is bad. It’s unsound. That’s what they described it as — unsound law. It needs to be removed and we’re going to harmonize with the European Patent Office. So before I — I’m just going on a bit of a rant here, standing on my soapbox telling you what you already know. But the Aerotel test essentially was — it was a four-step test, past tense. So you firstly had to construe the claim. That’s pretty straightforward. Then you actually had to identify the actual contribution. This is what they said — identify the contribution. Really in this aspect, you’re asking what, as a matter of substance rather than form, the inventor has added to human knowledge. So that’s what they said the contribution was. And then they said, the next step in Aerotel was to ask, well, does that contribution fall solely within the excluded subject matter field or realm? And then they said, well, if you get through that question, then you check the actual contribution or the alleged contribution to see whether it’s technical in nature. So that’s the Aerotel test as it was. And what the Supreme Court in their unanimous final decision said was that Aerotel at best jumbles up the order. It reverses the logical order of the analysis by starting with the contributions and then addressing the Article 52 exclusions. And then finally it goes back to what the technical nature of the invention is about. So they really went, no, we don’t like any of this stuff. It’s bad, it’s stupid, it puts the cart before the horse. So, in the intervening period between finding the case and actually seeing it progress all the way to the Supreme Court, we obviously had the G1/19 decision from the EPO Enlarged Board. And they basically said that they are going to validate any hardware as the approach. And that’s essentially what the UK also went with. The UK Supreme Court said we’re going to say that the threshold of patentability — or the exclusion to patentability — is simply overcome by the inclusion in a claim of any piece of hardware, whether it’s a processor or a piece of memory or whatever. It doesn’t matter. Any hardware makes the invention a technical invention. So it’s a really low threshold to consider. And they then went, well, actually, if we now align and harmonize with the European Patent Office sensibly, then we need to look at how we assess inventive step, which is the other thing that we raised with the Supreme Court. In fact, we probably raised it at other times and in all the other instances as well, but it came to a head at the Supreme Court. So the Supreme Court then also went a bit further and said, well, actually, whilst we do like the global approach to assessing inventive step for all fields of technology — whether it’s chemistry or biotech or electronics or software or AI — we use a test called Pozzoli. So that isn’t problem-solution. We don’t like problem-solution. We think it’s not codified in the European Patent Office. It’s just a mechanism that the EPO has come up with to try to objectively assess inventive step. We don’t particularly think that’s appropriate. We like our approach called Pozzoli. That’s it. So we’re going to say with Pozzoli, however, in order to actually understand — particularly in the context of mixed inventions having technical and non-technical features — it’s necessary for the examiner to undertake the so-called intermediate step, where you have to look at the interactions between features within a claim. The invention is defined by the claim. That’s what the act says. That’s what everyone understands. It’s the invention defined by the claim. So you look at the claim features and then you have to understand the interactions that take place. And even if they are between technical and non-technical features, if they bring about an overall technical effect when you consider the invention as a whole, then your claim should be good and you can assess it for classical inventive step. So that’s really where we’re at. There’s a lot to unpack there already. It’s probably a podcast in its own right, but that’s the positive history of where we’re at. And I can keep going if you wish me to for a second and talk about why I think this is — we’ll just contrast it quickly with the problem-solution approach at the EPO and COMVIK. So for inventions in the computer-implemented field, they use COMVIK and the problem-solution approach. The Supreme Court said, as I said, they don’t like problem-solution. I think the problem-solution issue is that it is also inherently pre-baked with hindsight because you have to look at the invention and then step back and exclude those features which are common. And then you formulate a problem based on the function that the claim achieves. And then you’re asking whether or not it would be obvious for a skilled person to arrive at the claimed invention, having been given that hindsight-developed problem. So COMVIK is not great by any means. And we know from a practical perspective that examiners are only too willing to look at a claim and simply line through features which they believe are non-technical, whereas they don’t actually look at the interaction of those features in the context of the claim as a whole. There is also a decision — very recent one actually, about a year ago — T 1249/22, where the Technical Board of Appeal told the examiners and the examining division, you cannot do this. It’s okay to have a claim directed towards an invention in a non-technical field, as long as the invention is directed to a technical solution of that problem. I think it’s paragraphs 11 and 12 or 10 of that decision that are worth looking at. But they’re saying that in all fields of technology, it doesn’t matter as long as the technical solution is about technology — therefore, you should be able to obtain a patent as long as there is a realistic and appropriate technical effect. Be careful actually, Bruce — I don’t mean technical contribution, I mean technical effect. There’s a reason for that distinction. Rolf Claessen: The non-technical features are nevertheless used to assess inventive step in the UK now after this decision, right? Bruce Dearling: Yes, that is the intermediate step. The decision says you must look at the invention as a whole. It’s the important thing. There are a couple of issues that arise out of this. The first one is that you have to provide context for the invention. The Supreme Court never provided any specific guidance about how we deal with the intermediate step or what the exact test is, which is in some respects fine. It seems to be fairly clear that you just have to engage your gray matter — your neurons — to work out what is going on in the real world. And once you work out what’s going on in the real world, what the benefits are, then you look at whether or not the actual implementation of the invention fundamentally has a technical flavor to it, which is not just coding, not just simple coding, but it does something smarter. There’s a real technical impetus. There’s a technical effect. Now that actually brings me onto something I’ve postulated or said. I think the intermediate step will follow something like what I’ve termed the holistic character test, which essentially is: work out what’s going on in the real world. Then once you’ve worked out what’s actually being achieved, what the benefits are, what the invention’s concerned with, then you ask the question, how am I achieving it technically? And how is there a technical effect? How does the technical effect arise? That brings out a couple of issues. The first one is that it’s actually about the word “contribution” because it depends on how the word is used. So if you look at head note one in COMVIK, it uses the word “contribute” — how the non-technical feature contributes to the invention. So that’s an additive inclusive concept. The UK IPO historically, and arguably at the moment today whilst they’re trying to retrain their 400 examiners — which this has caused them to have to do — their idea of contribution is this backward-looking concept. So technical contribution and technical effect, I think — although we mix them up and interchange them — are distinct. Technical contribution: you’re looking backwards. Technical effect is what you look at when you look forward into what’s going on. So this is subtle — it’s really subtle, but it’s important. And once you realize that you are actually looking for the technical effects, then you’re on much safer ground. It’s much more objective in terms of the assessment. This might be somewhat contentious, because it’s the way I’m looking at this, but I’ve been working on this a long, long time and thinking about it for probably decades, worryingly so. So technical contribution and technical effects are probably not the same, where they are interchangeably used to mean the same thing within existing decisions. Rolf Claessen: And in the beginning you said, now that Aerotel is dead basically, it’s more harmonized with the EPO’s approach. But what I take from the discussion now is that maybe — especially in view of the problem-solution approach — it’s not fully harmonized with the EPO’s approach at the moment, right? Or did the UK Supreme Court get something wrong, or was that a desired outcome from your point of view that this is not so completely harmonized with the EPO? Bruce Dearling: Well, the EPO — the any-hardware solution is fully harmonized, no doubt. So it’s now a question of inventive step under Article 56 or Section 3 of the Act. The EPC nowhere mandates the use of problem-solution. And we know that there are many different ways of actually assessing inventive step, including the concrete elaboration test from last year and problem-of-invention approaches. So there are numerous ways of assessing inventive step. So the UK says, “Pozzoli — we like Pozzoli.” Interestingly, I had a discussion with someone I probably can’t mention. They’re saying that the UK approach may actually be more permissive now. It might even influence how the EPO operates. So they may move away from COMVIK towards more of a Pozzoli approach, which basically says this: You identify the notion of the skilled person — step one. You identify the common general knowledge of that skilled person — step one B. You identify the inventive concept of the claim in question, where you construe it if you can’t work out what it is. You then identify what the differences are. And then you ask the question, is it obvious to the skilled person, given knowledge of the common general knowledge? This is entirely not artificial because, as I said beforehand, when you look at problem-solution, you are formulating a problem by backtracking from what the claimed invention is to a situation where you say, well, these are the common features and I’m going to project a problem to try and solve. Now that is already tainted with hindsight reasoning. It’s not safe, it’s not thoroughly objective. There is an inherent problem with this which sees good inventions cast by the wayside. Although it’s a preferred mechanism, it’s not fully baked. There are situations where examiners are inherently lazy, or they just simply use something like the requirements specification argument, which is just factual. It just demonstrates that they can’t be bothered to actually argue it properly or think about what the invention is. Sorry to any examiners listening to this, but this is just my personal view, that sometimes there are problems. I’m reminded of a quote from an EPI hearing I was at a long time ago, where the Legal Board of Appeal member said: “We understand that examining divisions can operate with a degree of mental laziness and that it’s too easy to throw too many things out of the basket when considering the issues of inventive step.” Now that one has stayed with me because you think — did someone just say that? And the answer is yes, they did. But it just goes to show that there is some tension between the TBA and the examining divisions, and they don’t always get it right. Rolf Claessen: So there might be a small difference now between the UKIPO’s future approach of assessing inventive step and the EPO? Bruce Dearling: Yeah, it might do. But the other interesting thing here — and thank you for pointing this out, I hadn’t entirely caught up with it, I’ve been traveling beforehand and I missed some of the UPC case law. So the UPC case law — in, was it — yeah, we talked about that. Rolf Claessen: Yeah. There was a decision in April, Abbott versus Sinocare. Bruce Dearling: Yeah, 901 of 2025. So a Court of Appeal decision from the UPC. It was APP_000000901, I believe, 2025. Decision 17th of April, hearing 27th of March. The UPC is not bound by — it’s a court. The European Patent Office is not a court, it’s an agency that administers and looks after the administrative rule of law. So the fact that this decision came out from the UK Supreme Court in February, and you see almost identical language used in the UPC decision, suggests that there is some alignment here, or some convergence in thought. Now, whilst the UPC decision also references G1/19 and uses problem-solution, there is enough — you’ve got to bear in mind that high-level courts do look at each other’s decisions. And this is really a question of influence and the desire to converge. So the fact that they’ve done this at this time is quite interesting. Again, I can’t quote someone directly from the EPO, although I would love to. They were saying — at a very high level — and they used the words “converge UPC practice towards UK Supreme Court practice on interpretation of the law.” So this may actually be happening in real time. Again, it would be wrong to actually refer to anyone by name, but it’s an observation that when I looked at the case, I can see why this is going ahead. And I can see why the judiciaries — they want to maintain independent judicial controls. They won’t reference the UK Supreme Court decision, not least because we’re not in the UPC. But if you look at the arguments in sections 106 and 107 of the UK Supreme Court’s Emotional Perception decision and head note one, you go — wow, this is very close. Rolf Claessen: Very close and nearly identical wording. Yeah. And the UPC also now uses non-technical features for assessing inventive step. Is that a problem for the EPO that has historically been aggressive in throwing out non-technical features for inventive step analysis? Bruce Dearling: Well, I think they really need to get to the situation — I don’t know — this holistic character test that I’m sort of proposing, where you really have to think about what the invention is achieving, and then look at how it’s technically being achieved. And then if you look at that again in the context of that other decision I mentioned — T 1249/22 — it says something like, in the case of an invention that amounts to a technical implementation of a non-technical method, provided the non-technical method does not contribute to the technical character of the invention. The board validated the approach of identifying the non-technical method and then goes through and says it’s patentable. There are decisions like this which suggest that examining divisions have to give it a bit more thought, because the Technical Board will realize that to satisfy the WTO requirements — which pretty much everyone is bound by — Article 27.1 TRIPS, which requires that you protect all fields of technology. And that means whether it’s data processing or business methods, because business methods can be patentable so long as they are implemented on a technical basis. That essentially seems to be what T 1249/22 is saying, although it doesn’t explicitly say “allowing business methods.” The exclusion is only “as such.” So does this decision, in combination with the Supreme Court case and the movement of the UPC, say: well, actually, let’s look at this properly? It requires objective assessments, not just superficial “let’s strike through that feature because I don’t like it, it looks non-technical.” Rolf Claessen: So are you hopeful that the EPO is adjusting and will reshape their case law in view of the UPC decision and the UK Supreme Court decision? Bruce Dearling: It’s a bit unfortunate that the corresponding UK case at the EPO was dropped by the applicants, because it was heading towards an examination hearing at the examining division. It would have gone to the TBA, and I’m sure it would then have gone from the TBA to the Enlarged Board. I’m pretty sure that’s the case. There is another case from the same client which will probably argue the same thing because the specs are almost identical. It’s just lagged in time. So is it going to change? I hope so, because I think the EPO have got it wrong — more often than not in this field. Well, maybe not more often than not — they get it wrong more times than they should do. Would I like to see it changed? Yes, I would, because I want the examiners to actually think about the technology as opposed to just — oh, it’s not — I don’t want to engage the gray matter. That serves no one. That doesn’t serve technology. That doesn’t serve industry. These patent rights are there for a reason. They are property rights. I’m referring to the award of the 2025 Nobel Prize for Economics — they are a core driver for society’s development. So the 2025 Nobel Prize was for something called creative destruction — the replacement of old technology with new — and it’s based on the patent paradigm. So all this stuff is coming to a head now. It’s just a question of how quickly the EPO actually catch up, and maybe they have something to catch up on. It’s just understanding that the examiners have to start to think. As I said, we’ve got the issues at the UKIPO where they’re going to have to retrain 400 examiners. Rolf Claessen: Yeah, right. Bruce Dearling: The Emotional Perception case wasn’t granted by the Supreme Court. They referred it back to the patent office for consideration under the intermediate step. So the patent office produced a response that I would describe as — I’d say arguably — not well reasoned, which I’ve filed the response to, which basically says you don’t really know what you’re talking about. What really worries me a bit is that I think they’re trying to introduce the Aerotel case through the back door. It’s backsliding. It’s a mechanism for trying to apply it in a different way or a different context, which would be wrong. I think they believe that the applicant will appeal this if they get a bad decision — they will appeal it back to the courts again via the High Court, Court of Appeal, Supreme Court route. I say maybe not. I say maybe the client will file what they call a judicial review, which is a nuclear option. That’s when you actually hold the Comptroller General of Patents to account and get full discovery of whether or not there’s internal documentation showing that they are deliberately circumventing the direction of the Supreme Court on the intermediate step. This is basically holding them to account and saying: if you’re not applying the intermediate step appropriately, you are in contempt of the law. So judicial review is a really serious thing to do, but it’s certainly something I would not exclude from consideration. We’ll see what happens. It’s not saying we’re just going to go through the courts and make them decide on this. We’re going to say you’re wrong. And there’s already enough evidence in the files to suggest that they are probably in contempt of court and they’re not applying the intermediate step appropriately. They may not know any better at the moment — they need to be guided — but the consequences for them are potentially severe. Rolf Claessen: I have another question for you. You were the instructing attorney — do you think the decision was perfect? What argument that you made was the most underappreciated by the court? And where do you think the judgment got it wrong, or was it all perfect? Bruce Dearling: No, it got 90% or 95% correct. The intermediate step is right. That’s the most important thing in the decision — it’s the intermediate step. The any-hardware thing — that’s logical, that makes some sense — but if people say “if the any-hardware rule is the important bit,” no it isn’t. It’s the intermediate step. That’s the important thing. Where do they go wrong? I think they went wrong because — and you’ve got to bear in mind that unlike German courts, I’ve got to be careful about how I express this — generally, as I understand it, and correct me if I’m wrong, but the judiciary in Germany on patent cases are generally more technically able. They’re normally technically qualified. I look at the Supreme Court justices and the Court of Appeal justices — we had one who was a humanities undergrad, one was a chemist. Good luck with trying to argue complex artificial neural network technologies, which are difficult even for me to understand. And I’ve been working in the field. They’re hard to understand. They require real understanding, real appreciation. They could say, well, actually we don’t need to look at the technology — but frankly, if you’re looking at the statutes and exclusions to patentability and asking what a computer program is, then you need to understand what these technical terms really are. And if you can’t, then the judgment is potentially flawed. Their finding that the neural network is a computer program is, I think, technically obtuse. You know that the Singaporean government — the Intellectual Property Office of Singapore — released about six weeks ago a consultation note to the Singaporean profession and population, asking: is the Emotional Perception case right, and do we need to adopt it into Singaporean national law? So this is direct soft power from the UK Supreme Court changing Commonwealth legislation and statutes. We’ll see what happens. But from what I’ve seen of a draft response from the attorneys, they’re saying essentially: we agree any hardware is right, the intermediate step is right. The assessment of the neural network as a computer program is wrong, or it just doesn’t make any sense. And I’ve made the same comments before in SIPA, in the relevant round in March. There’s a disconnect. I mean, it’s like they equate a computer program with being able to be run on an analog computer. Now, an analog computer has no central processing unit. An analog computer just has resistors and transistors and capacitors. So if they’re saying that an analog computer can run a program — that’s essentially what they’re saying in part of the judgment. Where is the program in an analog computer? And if they’re saying it’s in the values of the resistors and the capacitors, then that has implications for any circuit we’ve got — it’s potentially a computer program — which is just madness, because it doesn’t sit well with the legislation and decisions we’ve looked at over the last 50 years. This is a real problem. It may be a storm in a teacup because you can overcome the objections by having any hardware, but it’s an argument they shouldn’t have been making. It seems to be abstract legal argumentation which has little credibility in my personal view, although it’s now law. It may be that someone can take that, have an argument with the Supreme Court, get them to fix this. The other thing is the EPO looks at a neural network as a mathematical method, and the UK now says it’s a computer program. Neither is right. The EPO is wrong as well. If you look at the actual decision which they regularly quote — the Vicom case — if you actually read the claim and look at the case, you see that it doesn’t make a huge amount of sense. A neural network has applied mathematics in it. It can be based on a computer program because it’s required to set up the learning objectives and the loss function. Mathematical processes — it tweaks the weighting factors of neurons over the course of the training epochs. But at the end of the day, if the function performed by the neural network is new and it’s directed towards a technical implementation which is technically relevant, then it shouldn’t fail for being a mathematical method. And I think the EPO guidelines actually say that. Even recommendations — the UK court said that a recommendation is not technical. Well, actually it is, because it’s data processing, and you’ve got to work out how does the data processing work to provide an improved recommendation? Again, it goes back to the T 1249/22 decision. There’s a whole raft of these things which are left not entirely resolved. There’s enough here to keep someone busy for a few more years. Rolf Claessen: Right. So I have a question for you now that we’ve talked about the decision of the UK Supreme Court and the UPC — the Unified Patent Court — with very, very similar wording. What do you say are the three most important takeaways for patent practitioners in the US, in Europe, in the UK, before the EPO? Are there any things that you really want patent practitioners to take away from our discussion here? Bruce Dearling: Yeah, okay. So first: make sure the claim has some structure in it. You need to have any hardware. That’s number one — in terms of claim drafting. In terms of the description, you really have to understand what the invention is about. And you’ve got to make sure that you explain what function is achieved by what piece of hardware, kit or software. And if you do that — don’t nickel-and-dime this by writing the claim first — I would suggest that you run into problems. You need to understand what the invention is about. And you need to make sure that the description is complete and full to describe the functionality and the effects that are achieved in the real world. And if you can do that, then you’re on a much sounder basis — much, much stronger. There’s a much stronger foundation for this. So that’s two things. Is there a third one? That’s me being a bit cheeky, but I suppose I know what’s going on. Rolf Claessen: Yeah, but maybe the third takeaway is that maybe the EPO will rethink the way — at least how AI inventions are assessed for inventive step. Bruce Dearling: Well, as I said to you before, it could be that that’s the case. I don’t want to repeat myself again. The word “permissive” was used in a conversation I had with respect to the UK Supreme Court approach. COMVIK fundamentally still breaks with me and has done for years, because the way it’s set up and the way it’s applied distorts fundamentally what the invention is about. And until such time as that distortion is removed, there is a problem of objectivity versus subjectivity. And I think that’s really what the EPO has to grapple with. It’s not an easy thing to deal with, but maybe there are things going on. Bruce Dearling: It’s not an easy thing to deal with. I don’t know who’s going to argue it. It would have been useful for me to still have the original case up and running at the EPO because these arguments would have been fleshed out. I’m pretty sure they would have been referred to the Enlarged Board. We would have got it resolved. So it’s whether or not I can now work this into the existing case to try and get the examining division to — well, they will refuse, I suspect. And then it’ll go to the TBA. And then the TBA will have to look at this, hopefully with the referrals to the Enlarged Board. And then that fixes the problem on a national and international basis. Rolf Claessen: Yeah. Let’s see. [Laughs] Bruce Dearling: No, we don’t know. I mean, you might have a different view. What do you think? Do you think COMVIK is fundamentally right or fundamentally wrong? Rolf Claessen: Well, I’m not so much into AI inventions. I’m a chemist and I usually deal with chemistry inventions. But from the discussion that we had, I think that the EPO might rethink their position. I don’t know. Let’s see. Let’s hope so. Bruce Dearling: Well, they liked it. They liked problem-solution. It’s been with us for 25 years. It suggests that it’s a compromise. It’s not mandated by the European Patent Convention — that’s the point. It’s something they think works. And these things only work until such time as someone comes along and says, actually, you’re wrong, and this is the reason. Rolf Claessen: Let’s see if they choose a different route at least for AI inventions. So Bruce, thank you very much for your insight and for talking about the case that you were involved in with the UK Supreme Court. Where could people reach you if they have more questions about this field — basically patents, AI protection in the UK and Europe — and if they want to ask you more questions about this case? Bruce Dearling: Sure. Through the Hepworth Brown website or my LinkedIn profile, I suppose. The Hepworth Brown website has an email link. I’m trying to post things on it as well to try and provide a bit more context. But if people have fundamental questions on this stuff, then I’m happy to try and answer them. I suppose that I can be considered to be quite knowledgeable in the area. Rolf Claessen: Right. Certainly more than I am. [Laughing] Bruce Dearling: So I was fortunate. As a consequence of the work I’m doing, I was appointed last year to the WIPO Standing Committee on Patents and Privacy. That was discussed for the issues of where WIPO goes and what the direction of the problems are that we have in high-tech areas. So there seems to be some degree of understanding that I might know what I’m talking about. I think I probably do. Rolf Claessen: Thank you, Bruce. Thank you very much for being on IP Fridays. Bruce Dearling: My pleasure. Thank you very much, Rolf.

This episode covers: Cardiology This Week: A concise summary of recent studies The heart in high altitude Mitral annular disjunction Mythbusters: Weekend mortality Host: Rick Grobbee Guests: JP Carpenter, Kristina Haugaa, Silvia Ulrich Want to watch that episode? Go to: https://esc365.escardio.org/event/2563 Want to watch that extended interview on mitral annular disjonction, go to: https://esc365.escardio.org/event/2563?resource=interview   Disclaimer ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Kristina Haugaa, Nicolle Kraenkel and Silvia Ulrich have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Rick Grobbee Guest: Kristina Haugaa Want to watch that extended interview on https://esc365.escardio.org/event/2563?resource=interview Go to: Want to watch that episode? Go to: https://esc365.escardio.org/event/2563   Disclaimer ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Kristina Haugaa and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Biomarkers in heart failure Digoxin in HFrEF Scientific Highlights from Heart Failure 2026 Host: Wilfried Mullens Guests: Lynne Stevenson, Dirk van Veldhuisen, Theresa McDonagh Want to watch that episode? Go to: https://esc365.escardio.org/event/2565 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. A ny views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel, Dirk van Veldhuisen and Lynne Warner Stevenson have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report:Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi.  Theresa McDonagh has declared to have potential conflicts of interest to report: honoraria from Boeringer Ingelheim. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Fluent Fiction - Japanese: Spring Rain Reveals Hidden Hearts at Fushimi Inari Shrine Find the full episode transcript, vocabulary words, and more:fluentfiction.com/ja/episode/2026-05-12-22-34-01-ja Story Transcript:Ja: ゴールデンウィークの明るい朝、光が朱塗りの鳥居を照らしていました。En: On a bright morning during Golden Week, light was illuminating the vermilion-painted torii.Ja: 伏見稲荷神社は、観光客で賑わいながらも、どこか静謐な雰囲気を持っていました。En: Fushimi Inari Shrine was bustling with tourists, yet it had a certain tranquil atmosphere.Ja: ハルトとユキは、一緒にこの神社を訪れていました。En: Harto and Yuki were visiting this shrine together.Ja: ハルトは自然と歴史を愛する思慮深い青年です。En: Harto is a thoughtful young man who loves nature and history.Ja: 心の中では多くの思いを抱いていました。En: Within his heart, he harbored many thoughts.Ja: その中の一つは、ユキへの手紙のことでした。En: Among them was the matter of a letter he had not given to Yuki.Ja: 長い間、彼はその手紙を渡せずにいました。En: For a long time, he had been unable to deliver the letter.Ja: 彼は変化を恐れていたからです。En: He feared change.Ja: 一方、ユキは冒険心に満ちた女性です。En: On the other hand, Yuki is a woman full of a spirit of adventure.Ja: 彼女はハルトに対して心の中で疑問を持っていました。En: She harbored questions about Harto in her heart.Ja: ハルトが自分に隠れた感情を持っているのではないかと感じていました。En: She felt that Harto might be hiding his feelings toward her.Ja: 彼女は二人の関係の真実を知りたかったのです。En: She wanted to know the truth about their relationship.Ja: 神社を歩いていると、突然、空が曇り始めました。En: As they walked through the shrine, suddenly, the sky began to cloud over.Ja: そして、大粒の雨が降り始めました。En: And then, large raindrops began to fall.Ja: ハルトとユキは急いで鳥居の下に隠れました。En: Harto and Yuki hurriedly took shelter under the torii.Ja: 雨はどんどん強くなり、神社から出ることができなくなりました。En: The rain grew heavier and they couldn't leave the shrine.Ja: 二人きりで静かな雨音を聞いていると、雰囲気が変わりました。En: As they listened to the quiet sound of the rain, the atmosphere changed.Ja: ハルトの心に大きな葛藤が訪れました。En: A great conflict arose in Harto's heart.Ja: 「今こそ、手紙を渡すべきだろうか。En: "Should I give her the letter now?Ja: それとも、何も言わずにいるべきだろうか。En: Or should I say nothing?"Ja: 」彼の心は揺れ動きました。En: His heart wavered.Ja: ハルトは小さいながらも決意を固め、手紙を取り出しました。En: Harto gathered his resolve, albeit small, and took out the letter.Ja: 「ユキ、これを読んでほしい。En: "Yuki, I want you to read this."Ja: 」そう言って、震える手で彼女に手紙を渡しました。En: With trembling hands, he handed her the letter.Ja: ユキは驚いて手紙を受け取りました。En: Yuki was surprised and accepted the letter.Ja: 雨の音の中で、彼女はゆっくりと封を切り、手紙を読み始めました。En: Amidst the sound of the rain, she slowly opened the seal and began to read the letter.Ja: 内容を読み進めるにつれて、彼女の顔に優しい笑顔が広がりました。En: As she read through the contents, a gentle smile spread across her face.Ja: 心の中で隠れていたハルトの気持ちが、はっきりと伝わったのです。En: Harto's hidden feelings in his heart were clearly conveyed.Ja: 雨が少しずつ弱まり始めました。En: The rain gradually began to weaken.Ja: 二人は穏やかな気持ちになり、しばらく鳥居の下でそのまま過ごしました。En: With a sense of calm, they remained there under the torii for a while.Ja: ハルトは初めて自分の気持ちを真っ直ぐに伝え、心が解き放たれるような気がしました。En: Harto, for the first time, conveyed his feelings directly, and felt as if his heart was set free.Ja: ユキはその思いを受け入れ、二人の関係は新しい一歩を踏み出しました。En: Yuki accepted those feelings, and their relationship took a new step forward.Ja: やがて雨が止み、二人は晴れやかな気持ちで神社を後にしました。En: Eventually, the rain stopped, and with bright spirits, they left the shrine.Ja: ハルトはその時初めて、真実を伝えることがどれほど大切かを理解しました。En: For the first time, Harto understood how important it is to convey the truth.Ja: たとえそれが変化をもたらすものであったとしても、それにより得られる絆の深まりを知ったのです。En: Even if it brings about change, he realized the deepening of bonds that could be gained from it.Ja: 伏見稲荷神社の千本鳥居の下で、二人は心を通わせ、新たな一歩を踏み出しました。En: Under the thousand gates of Fushimi Inari Shrine, the two connected their hearts and took a new step forward.Ja: この春の雨は、ただの自然現象ではなく、それぞれの心を打ち明けるきっかけとなったのです。En: This spring rain was not merely a natural phenomenon; it became the catalyst for revealing their hearts to each other. Vocabulary Words:illuminating: 照らしていましたvermilion: 朱塗りbustling: 賑わいtranquil: 静謐thoughtful: 思慮深いharbored: 抱いていましたdeliver: 渡せずspirit of adventure: 冒険心cloud over: 曇り始めましたraindrops: 大粒の雨shelter: 隠れましたatmosphere: 雰囲気conflict: 葛藤wavered: 揺れ動きましたresolve: 決意trembling: 震えるseal: 封conveyed: 伝わったcalm: 穏やかなset free: 解き放たれるdeepening: 深まりcatalyst: きっかけreveal: 打ち明けるphenomenon: 現象gathered: 取り出しましたaccepted: 受け取りましたgradually: 少しずつremained: 過ごしましたunderstood: 理解しましたbonds: 絆

Host: Wilfried Mullens Guest: Marc Dweck Want to watch that extended interview on https://esc365.escardio.org/event/2564?resource=interview Go to: Want to watch that episode? Go to: https://esc365.escardio.org/event/2564   Disclaimer ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Antonio Greco and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Marc Dweck has declared to have potential conflicts of interest to report: consultancy fees from Novartis, Silence, and AstraZeneca related to aortic stenosis and development of a medical therapy. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Genetics and genetic testing in HCM Asymptomatic aortic valve stenosis Statistics Made Easy: Mediation analysis Host: Wilfried Mullens Guests: JP Carpenter, Caroline Coats, Marc Dweck Want to watch that episode? Go to: https://esc365.escardio.org/event/2564 Want to watch that extended interview on asymptomatic aortic valve stenosis, go to: https://esc365.escardio.org/event/2564?resource=interview   Disclaimer  ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails.  ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.    Declarations of interests Stephan Achenbach, Yasmina Bououdina, Antonio Greco and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Caroline Coats has declared to have potential conflicts of interest to report: in the last 5 years, consultant/advisor to Bayer, Bristol Myers Squibb, Cytokinetics, Sanofi, Roche Diagnostics. Marc Dweck has declared to have potential conflicts of interest to report: consultancy fees from Novartis, Silence, and AstraZeneca related to aortic stenosis and development of a medical therapy. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Fushimi Inari Taisha est le plus grand sanctuaire shinto du Japon situé au sud de Kyoto. Erigé en 711, il est dédié à la déesse du riz Inari et plus largement à la richesse. La beauté de ce complexe se dévoile au gré d'une randonnée pédestre le long d'une vallée, balisée par des milliers de portiques vermillon appelés torii. Kelly, Marjorie et Charly vous en disent plus sur cet incontournable de la ville de Kyoto. 03:10 Présentation de Fushimi Inari Taisha21:30 La randonnée de Fushimi Inari Taisha34:10 Les activités à faire aux alentours40:16 Conclusion

This episode covers: Cardiology This Week: A concise summary of recent studies Time for physiological pacing in heart failure? Same-day discharge after EP procedures: from evidence to practice EHRA 2026 Scientific Highlights Host: Gerd Hindricks Guests: Haran Burri, Emma Svennberg, Julia Vogler Want to watch that episode? Go to: https://esc365.escardio.org/event/2555    Disclaimer ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video.  The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Haran Burri has declared to have potential conflicts of interest to report: institutional research and fellowship support or speaker honoraria from Abbott, Biotronik, Boston Scientific, Medtronic, Microport. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honorary from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Gerd Hindricks has declared to have potential conflicts of interest to report: institutional research and fellowship support or speaker honoraria from Abbott, Biotronik, Boston Scientific, Medtronic, Microport. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Helmut Puererfellner has declared to have potential conflicts of interest to report: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities for the following companies: Abbott, Biotronik, Biosense Webster, Boston Scientific, Daiichi Sankyo, Medtronic. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson. Julia Vogler has declared to have potential conflicts of interest to report: honoraria for talks: Abbott.

In questo episodio di Ti leggiamo una femminista attraversiamo Non anima viva, un romanzo ambientato in un piccolo paese del trapanese, tra campagne assolate e silenzi che pesano come condanne. Claudia ed Elvira, due sorelle adolescenti, si ritrovano sole: la madre è fuggita, il padre è assente, la comunità osserva e giudica. Attorno a loro si muove un sistema fatto di vergogna, controllo e non detti, in cui crescere significa imparare troppo presto a difendersi. Abbiamo parlato di questo: di famiglia come luogo di violenza e sopravvivenza, di corpo come primo spazio di conflitto, di desiderio, di silenzio e di ribellione. Perché Non anima viva non è un romanzo di formazione, ma di rottura: racconta cosa succede quando iniziare a crescere significa imparare a dire no. È la prima volta che portiamo un romanzo dentro TLUF, e siamo curiosissime di sapere cosa ne penserete. Buon ascolto. Per sostenere il progetto seguici su instagram! Basterà digitare il nostro nome tutto attaccato per scoprire un sacco di cose che ci riguardano, compreso un gruppo Telegram in cui invitiamo a iscriverti. Puoi anche ofrrirci un caffè sul nostro profilo KO-FI oppure con una donazione diretta tramite Paypal alla nostra mail: tileggiamounafemminista@gmail.com

This episode covers: Cardiology this Week: A concise summary of recent studies What's new in hypertension? Why I favour a critical approach in cardiology Snapshots Host: Sabiha Gati Guests: Konstantinos Koskinas, Gianfranco Parati, John Mandrola, Yasmina Bououdina Want to watch this episode? Go to: https://esc365.escardio.org/event/2561 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Sabiha Gati, Nicolle Kraenkel and John Mandrola have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: honorary from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi.  Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Gianfranco Parati has declared to have potential conflicts of interest to report: Merck Sharp and Dohme, Omron Healthcare, Viatris. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Sabiha Gati Guest: Gianfranco Parati Want to watch this extended interview? Go to: https://esc365.escardio.org/event/2561?resource=interview Want to watch the episode? Go to: https://esc365.escardio.org/event/2561 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Sabiha Gati and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: honorary from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi.  Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Gianfranco Parati has declared to have potential conflicts of interest to report: Merck Sharp and Dohme, Omron Healthcare, Viatris. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This Special Episode on Atrial Fibrillation covers: Cardiology this Week: A concise summary of recent studies Atrial fibrillation burden: clinical relevance of a new outcome Pulsed field ablation: game changer? Drug treatment following atrial fibrillation ablation Spotlight: Holiday Heart Syndrome Host: Rick Grobbee Guests: Rick Grobbee, Konstantinos Koskinas, Jason Andrade, Arian Sultan, Michiel Rienstra Want to watch that special episode? Go to: https://esc365.escardio.org/event/2549 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Jason Andrade, Yasmina Bououdina, Rick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Michiel Rienstra has declared to have potential conflicts of interest to report: consultancy fees from Bayer (OCEANIC-AF national PI) , InCarda Therapeutics (RESTORE-SR national PI), Novartis to the institution. Speaker fee from Daiichi-Sankyo, Pfizer to the institution. Unrestricted research grant from the Dutch Heart Foundation and is conducted in collaboration with and supported by the Dutch CardioVascular Alliance, 01-002-2022-0118 EmbRACE. Unrestricted research grant from ZonMW and the Dutch Heart Foundation; DECISION project 848090001. Unrestricted research grants from the Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation; RACE V (CVON 2014–9), RED-CVD (CVON2017-11). Unrestricted research grant from Top Sector Life Sciences & Health to the Dutch Heart Foundation (PPP Allowance; CVON-AI (2018B017). Unrestricted research grant from the European Union's Horizon 2020 research and innovation programme under grant agreement; EHRA-PATHS (945260). This research is funded by the Dutch Heart Foundation and is conducted in collaboration with and supported by the Dutch CardioVascular Alliance, 01 -002 -2022 -0118 EmbRACE.  Emma Svennberg has declared to have potential conflicts

Host: Sabiha Gati Guest: Thomas F. Luescher Want to watch that extended interview on The future of guidelines in an era of Big Data and AI, go to: https://esc365.escardio.org/event/2556?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/2556 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode.  The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Sabiha Gati, Nicolle Kraenkel and Thomas F. Luescher have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology this Week: A concise summary of recent studies The future of guidelines in an era of big data and AI Exercise in hypertrophic cardiomyopathy Snapshots Host: Sabiha Gati Guests: Kostas Koskinas, Thomas F. Luescher, Michael Papadakis, Stephan Achenbach Want to watch that episode? Go to: https://esc365.escardio.org/event/2556 Want to watch the extended interview on The future of guidelines in an era of Big Data and AI, go to: https://esc365.escardio.org/event/2556?resource=interview Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode.  The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Sabiha Gati, Nicolle Kraenkel and Thomas F. Luescher have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Did you know that gene edited wheat is already being trialled in Australia?

In this episode, Robin Merttens sits down with Frank Perkins, CEO and Co-founder of inari, to explore what it really takes to build and scale a modern MGA in 2026.  From founding an insurance business himself to leading a technology company serving specialist MGAs across Europe, Frank brings a rare dual perspective. He understands both the pressure of getting premium through the door and the responsibility of building systems that underwriters actually want to use.  As private equity capital accelerates into the sector and niche, digital-first MGAs proliferate across continental Europe, the conversation turns to speed, integration and the quiet evolution of the underwriting workbench.  In this conversation, Frank shares:  Why technology literacy is now firmly in the hands of business users, not just IT departments  How the rise of highly specialised MGAs is reshaping what underwriting platforms need to deliver  Why “rip and replace” transformation programmes are giving way to orchestration and coexistence  How AI is materially accelerating integrations and onboarding, cutting rollout times from months to days  The difference between generic AI tooling and insurance-specific intelligence  Why speed of execution is becoming a defining competitive advantage  What a tightening market cycle will mean for operational efficiency  Why continental Europe may offer the next major growth wave for MGAs  How culture and domain expertise can matter as much as code in a crowded market  If you like what you're hearing, please leave us a review on whichever platform you use or contact Robin Merttens on LinkedIn.  Sign up to the InsTech newsletter for a fresh view on the world every Wednesday morning.

This episode covers: Cardiology This Week: A concise summary of recent studies Atrial septal defects in adults Conservative and invasive management of chronic coronary syndromes Milestones: 4S trial   Host: Rick Grobbee Guests: JP Carpenter, Annemien van den Bosch, Rasha Al-Lamee, Roxana Mehran Want to watch the episode? Go to: https://esc365.escardio.org/event/2552 Want to watch the extended interview on Atrial septal defects in adults, go to: https://esc365.escardio.org/event/2552?resource=interview Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Nicolle Kraenkel and Annemien van den Bosch have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Rasha Al-Lamee has declared to have potential conflicts of interest to report:speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir, Astrazeneca. Consulting Fees: Menarini pharmaceuticals, Abbott, Philips, Shockwave, Elixir, IsomAB, VahatiCor, SpectraWave, AstraZeneca, Cathworks, Janssen Pharmaceuticals. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Roxana Mehran has declared to have potential conflicts of interest to report: institutional research payments from Abbott, Alleviant Medical, Chiesi, Concept Medical, Cordis, CPC Clinical Research, Daiichi Sankyo, Duke, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, Janssen, MedAlliance, Medtronic, NewAmsterdam Pharma, Novartis, Novo Nordisk Inc., Population Health Research Institute (PHRI), Protembis GmbH, Radcliffe, RM Global Bioaccess Fund Management, Sanofi US Services, Inc. ; personal fees from: None ; Equity

Host: Rick Grobbee Guest: Annemien van den Bosch Want to watch that extended interview on Atrial septal defects in adults, go to: https://esc365.escardio.org/event/2552?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/2552 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Nicolle Kraenkel and Annemien van den Bosch have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson

Playlist: The Pharcyde, Mogier - Oh Shit (Mogier Edit)Marlon Hoffstadt, DJ Daddy Trance - It's That Time (FISHER Extended Mix)Fergie, Aenna Caelum, Sir Gio - U Fergalicious (AENNA CAELUM & SIR GIO MASHUP)Kendrick Lamar, Jahir - Not Like Us Snippet (Jahir Edit)LL Cool J, Mark B - Goin Back To Cali (Mark B. Bootleg)Mason Flint - Hey Mama (Extended Mix)Sonny Fodera, Gorgon City, Haya T - Moving Blind (Gorgon City Remix) [HayaT Edit]Redlight, NOURIEGA - 9TS (NOURIEGA REMIX)Blackeyed Peas, Unloaded - SATURDAY SHOUT (Unloaded Edit)X Eliot - Eyes Open WideKendrick Lamar, Kelland & Jaemo - m.A.A.d city (Kelland & Jaemo Remix)Rob Base + DJ E-Z Rock, Curlyheads - It Takes Two (Curlyheads Edit)AJ & BIG JUSTICE, KELLAND - BRING THE BOOM (KELLAND REMIX)Spencer & Hill vs. Ookay - CantinaBillie Eilish, Phrva - LUNCH (Phrva Flip)Casey Club - Nasty (Bootleg)Chappell Roan, Inari, Just John - HOT TO GO! (Inari x just john Flip)Darby & OOTORO - PARTY (VIP)FLY - PUSH FLIPShip Wreck, costa x rj wlkr - function (costa x rj wlkr)Hamdi - Skanka (Original Mix)John Summit, Artifakts - LIGHTS GO OUT [Artifakts Bootleg]LEVITYL, NITTI - LIKE THIS FREAKY REMIXSIDEQUEST - UPNDOWNDarude, Killsafari - SANDSTORM (KILLSAFARI REMIX)Hanumankind & Kalmi - Run It UpXRAY - YOSEMITEBorne, Taiki Nulight - Out Of ControlCHRYSTAL, Notion - THE DAYS (Notion Remix)Packet Loss - Lyrics BootlegSir Spyro , Killa P - Start & Stop (Original Mix)Sammy Virji, Fred again.. - Winny (Original Mix)Fatboy Slim, Bvnquet - Star 69 (Bvnquet Edit)ance - Front-2-Back-(Edit)longstoryshort - Don't Do It (Extended Mix)Arlo, Chris Lake, Aatig - In the Yuma (Arlo Flip)Human Movement, BouKi - Sunshine (Original Mix)Icon - KetiovMAD QUEEN - MAKE A DANCEJackyboom - Space FunkNOTION, Willow Kayne - WAITING

Playlist: The Pharcyde, Mogier - Oh Shit (Mogier Edit)Marlon Hoffstadt, DJ Daddy Trance - It's That Time (FISHER Extended Mix)Fergie, Aenna Caelum, Sir Gio - U Fergalicious (AENNA CAELUM & SIR GIO MASHUP)Kendrick Lamar, Jahir - Not Like Us Snippet (Jahir Edit)LL Cool J, Mark B - Goin Back To Cali (Mark B. Bootleg)Mason Flint - Hey Mama (Extended Mix)Sonny Fodera, Gorgon City, Haya T - Moving Blind (Gorgon City Remix) [HayaT Edit]Redlight, NOURIEGA - 9TS (NOURIEGA REMIX)Blackeyed Peas, Unloaded - SATURDAY SHOUT (Unloaded Edit)X Eliot - Eyes Open WideKendrick Lamar, Kelland & Jaemo - m.A.A.d city (Kelland & Jaemo Remix)Rob Base + DJ E-Z Rock, Curlyheads - It Takes Two (Curlyheads Edit)AJ & BIG JUSTICE, KELLAND - BRING THE BOOM (KELLAND REMIX)Spencer & Hill vs. Ookay - CantinaBillie Eilish, Phrva - LUNCH (Phrva Flip)Casey Club - Nasty (Bootleg)Chappell Roan, Inari, Just John - HOT TO GO! (Inari x just john Flip)Darby & OOTORO - PARTY (VIP)FLY - PUSH FLIPShip Wreck, costa x rj wlkr - function (costa x rj wlkr)Hamdi - Skanka (Original Mix)John Summit, Artifakts - LIGHTS GO OUT [Artifakts Bootleg]LEVITYL, NITTI - LIKE THIS FREAKY REMIXSIDEQUEST - UPNDOWNDarude, Killsafari - SANDSTORM (KILLSAFARI REMIX)Hanumankind & Kalmi - Run It UpXRAY - YOSEMITEBorne, Taiki Nulight - Out Of ControlCHRYSTAL, Notion - THE DAYS (Notion Remix)Packet Loss - Lyrics BootlegSir Spyro , Killa P - Start & Stop (Original Mix)Sammy Virji, Fred again.. - Winny (Original Mix)Fatboy Slim, Bvnquet - Star 69 (Bvnquet Edit)ance - Front-2-Back-(Edit)longstoryshort - Don't Do It (Extended Mix)Arlo, Chris Lake, Aatig - In the Yuma (Arlo Flip)Human Movement, BouKi - Sunshine (Original Mix)Icon - KetiovMAD QUEEN - MAKE A DANCEJackyboom - Space FunkNOTION, Willow Kayne - WAITING

Host: Emer Joyce Guest: Borge Nordestgaard Want to watch that extended interview on Lp(a) and aortic valve stenosis, go to: https://esc365.escardio.org/event/2548?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/2548 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Borge Nordestgaard has declared to have potential conflicts of interest to report: consultancies/talks for AstraZeneca, Sanofi, Ionis, Amgen, Amarin, Novartis, Novo Nordisk, Esperion, Lilly, Arrowhead, Marea, Merck, Torrent, USV – honoraria used for research. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Lp(a) and aortic valve stenosis The truth about climate change and heart disease Snapshots Host: Emer Joyce Guests: JP Carpenter, Borge Nordestgaard, Hugh Montgomery, Stephan Achenbach Want to watch that episode? Go to: https://esc365.escardio.org/event/2548 Want to watch that extended interview on Lp(a) and aortic valve stenosis, go to: https://esc365.escardio.org/event/2548?resource=interview Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1.  Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Hugh Montgomery has declared to have potential conflicts of interest to report: funded and runs the charity-funded non-profit 'Real Zero'. Unpaid co-chair of the UK Health Alliance on Climate Change, Lancet Countdown on Health and Climate Change. Borge Nordestgaard has declared to have potential conflicts of interest to report: consultancies/talks for AstraZeneca, Sanofi, Ionis, Amgen, Amarin, Novartis, Novo Nordisk, Esperion, Lilly, Arrowhead, Marea, Merck, Torrent, USV – honoraria used for research. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Fluent Fiction - Japanese: Snow and Tradition: A Setsubun Journey at Fushimi Inari Find the full episode transcript, vocabulary words, and more:fluentfiction.com/ja/episode/2026-02-02-23-34-02-ja Story Transcript:Ja: 冬の朝、京都の伏見稲荷大社には、雪が静かに降り積もっていました。En: On a winter morning, snow was quietly piling up at Fushimi Inari Taisha in Kyoto.Ja: 千本鳥居が続く道は、雪で白く輝き、神秘的な雰囲気を漂わせています。En: The path lined with a thousand torii gates shone white with snow, exuding a mystical atmosphere.Ja: 大学生の遥は、その光景を見つめながら、心を引き締めました。En: Haruka, a university student, looked at the scene and steeled her heart.Ja: 彼女のテーマは、日本の伝統的な祭りについての論文です。En: Her thesis is on Japan's traditional festivals.Ja: 節分の祭りから学ぶことは、彼女の考えを新たにします。En: Learning from the Setsubun festival provides her with new insights.Ja: 伏見稲荷で準備が進む中、遥は案内役のサトシと出会いました。En: As preparations progressed at Fushimi Inari, Haruka met Satoshi, her guide.Ja: 彼は地元のガイドで、神道の祭りに情熱を持っていました。En: He was a local guide with a passion for Shinto festivals.Ja: しかし、サトシは最初、遥に心を開きませんでした。En: However, Satoshi did not initially open his heart to Haruka.Ja: 以前、外部の人々が祭りの神聖な雰囲気を乱したことがあったのです。En: In the past, outsiders had disrupted the sacred atmosphere of the festival.Ja: 遥は考えました。「どうすればサトシさんの信頼を得られるだろうか？」En: Haruka thought to herself, "How can I earn Satoshi-san's trust?"Ja: そこで彼女は、サトシのツアーに参加することを決めました。En: So she decided to join Satoshi's tour.Ja: さらに、祭りの準備を手伝うことにしました。En: Furthermore, she decided to help with the festival preparations.Ja: 彼女の一生懸命な姿に、サトシは少しずつ心を動かされました。En: Seeing her earnest efforts, Satoshi's heart slowly began to change.Ja: 節分の夜、境内は賑やかでした。En: On the night of Setsubun, the temple grounds were lively.Ja: 鬼を追い払うため、「鬼は外、福は内」と人々が豆を撒きます。En: To drive away demons, people scattered beans while chanting "Oni wa soto, fuku wa uchi"—"Demons out, fortune in."Ja: 遥はその光景に魅了され、サトシの指導の下、共に祭りを楽しみました。En: Haruka was captivated by the scene and, under Satoshi's guidance, enjoyed the festival together.Ja: お互いの信頼が深まり、サトシはついに遥に伝統の裏話や、あまり知られていない儀式を教えてくれました。En: Their mutual trust deepened, and Satoshi finally shared with Haruka stories behind the traditions and lesser-known rituals.Ja: 例えば、伏見稲荷での特別な豆まきの仕方や、お守りの意味について、サトシ自身の体験を織り交ぜて話しました。En: For example, Satoshi talked about the special way of bean-throwing at Fushimi Inari and the meaning of the omamori, weaving in his personal experiences.Ja: 遥はメモを取りながら感謝の気持ちを忘れずに伝えました。En: Haruka took notes and expressed her gratitude without forgetting to do so.Ja: 翌日、祭りは終わり、静けさが戻りました。En: The next day, the festival ended, and tranquility returned.Ja: 遥は充実した心持ちで京都を後にしました。En: Haruka left Kyoto with a fulfilled heart.Ja: 彼女の論文には、祭りの真髄と日本文化の深さが反映されるでしょう。En: Her thesis will reflect the essence of the festival and the depth of Japanese culture.Ja: サトシもまた、伝統を大切にする人と共有する価値を再確認しました。En: Satoshi also reaffirmed the value of sharing traditions with those who cherish them.Ja: 遥とサトシの心はつながりました。En: The hearts of Haruka and Satoshi connected.Ja: 文化の橋渡しは、新しい信頼と理解をもたらしました。En: The cultural bridge brought about new trust and understanding.Ja: この経験から、どちらもそれぞれの成長を感じました。En: From this experience, both felt their own growth.Ja: そして、伏見稲荷は、彼らの出会いを静かに見守り続けました。En: And Fushimi Inari continued to quietly watch over their encounter. Vocabulary Words:atmosphere: 雰囲気mystical: 神秘的steel: 引き締めるthesis: 論文insight: 考えpreparation: 準備initially: 最初disrupt: 乱すearnest: 一生懸命captivated: 魅了されるchanting: 唱えるdemons: 鬼fortune: 福trust: 信頼rituals: 儀式weaving: 織り交ぜるgratitude: 感謝tranquility: 静けさfulfilled: 充実したessence: 真髄reaffirmed: 再確認するcherish: 大切にするencounter: 出会いbridge: 橋渡しgrowth: 成長scattered: 撒くguide: 案内役participate: 参加するexpress: 伝えるtraditions: 伝統

Looking for a smarter way to travel and a richer way to live when you get back? We're launching Season Eight with A for Airbnb, sharing how a long road trip through Finland and Norway transformed from a checklist of sights into a string of homes. From a lakeside house with a wood-fired sauna in Puolanka to an RV in the Inari village, from the Arctic Circle at Rovaniemi to Norway's brooding fjords, we used Airbnbs to slow down, meet neighbors, and absorb the quiet routines that define Nordic life.Along the way we chased the northern lights near Levi, learned why Finnish apartments feel so peaceful, and discovered how to spot the small details that make a stay effortless: strong Wi‑Fi, laundry days, clear entry instructions, local tips, and respectful house norms. Historic Kittilä surprised us with an artist-host who kept stories alive along with salvaged wood and open-hearth cooking. Oulu and Turku balanced old-town charm with modern coffee culture and kid-friendly spaces. The big takeaway wasn't a single perfect property; it was how the right stay turns a map into a neighborhood and a night into a lesson you can use at home.We also flip the script and talk about hosting. Back in Waco, our 1916 fixer-upper doubles as an Airbnb where guest nights help fund restoration. We share our playbook for five-star experiences on both sides: how to filter and book smarter, how to be a great guest who communicates and respects the space, and how hosts can elevate comfort with small, thoughtful touches like printed Wi‑Fi, bedside charging, clear guides, and a warm welcome. Subscribe now, share with a travel-loving friend, and tell us: what's the one feature that makes a place feel like home to you?PParikkalaPuolanka, FinlandRovaniemiInariKarisjokeBalsfjord Kommune, NorwayKittiläOuluTurkuWaco, TX - https://www.airbnb.com/h/historicwacoPlease support our show by shopping through Eagle Creek: https://alnk.to/gVNDI6N and/or feel free to donate to:http://paypal.me/TheROAMies And it means the world to us when you subscribe, rate and share our podcast. Alexa and RoryThe ROAMiesFollow us at:http://www.TheROAMies.com@The ROAMies: Facebook and Instagram YouTube and X.

A new week means new questions! Hope you have fun with these!What candy saw a 65% increase in sales within 2 weeks of the release of the movie "ET"?Which morning talk show host was the spokesperson for Carnival Cruise Line from the late 80s to early 90s with the catchphrase "If my friends could see me now"?What is the name of Lativia's capital that shares its name with a the gulf it lies on?Karl Bushby, an English ex-paratrooper, has been walking since November 1998 in an attempt to be the first person to walk a completely unbroken path around the world. By what large biblical name does his expedition go by?Baseball player Ty Cobb had what fruity nickname owing to his home state origin?Maya Lin was an undergraduate at Yale University when she won the contest to design which memorial?What is the term for the broad group of organic compounds that include fats, waxes, sterols, and fat-soluble vitamins?“Go ahead, make my day” was spoken by Clint Eastwood in which movie?“The creatures outside looked from pig to man, and from man to pig, and from pig to man again; but already it was impossible to say which was which.” is the last line from which novel?Which international agreement of 1864 regulated the treatment of those wounded in war?Inari is the god of what grain in Japense mythology?What country has the most islands in the world?On the London Underground map, what color is the circle line?On Swiss cars, there are stickers with the letters "CH", what does "CH" stand for?To help them develop better space suits, NASA studied the newborns of what animal, whose leg blood vessels thicken quickly, allowing them to walk within the first hour after birth?Which bird has the largest egg to body ratio?MusicHot Swing, Fast Talkin, Bass Walker, Dances and Dames, Ambush by Kevin MacLeod (incompetech.com)Licensed under Creative Commons: By Attribution 3.0 http://creativecommons.org/licenses/by/3.0/Don't forget to follow us on social media:Patreon – patreon.com/quizbang – Please consider supporting us on Patreon. Check out our fun extras for patrons and help us keep this podcast going. We appreciate any level of support!Website – quizbangpod.com Check out our website, it will have all the links for social media that you need and while you're there, why not go to the contact us page and submit a question!Facebook – @quizbangpodcast – we post episode links and silly lego pictures to go with our trivia questions. Enjoy the silly picture and give your best guess, we will respond to your answer the next day to give everyone a chance to guess.Instagram – Quiz Quiz Bang Bang (quizquizbangbang), we post silly lego pictures to go with our trivia questions. Enjoy the silly picture and give your best guess, we will respond to your answer the next day to give everyone a chance to guess.Twitter – @quizbangpod We want to start a fun community for our fellow trivia lovers. If you hear/think of a fun or challenging trivia question, post it to our twitter feed and we will repost it so everyone can take a stab it. Come for the trivia – stay for the trivia.Ko-Fi – ko-fi.com/quizbangpod – Keep that sweet caffeine running through our body with a Ko-Fi, power us through a late night of fact checking and editing!

Fluent Fiction - Japanese: Mystery of the Missing Fox: Fushimi Inari's Snowy Secret Find the full episode transcript, vocabulary words, and more:fluentfiction.com/ja/episode/2025-12-08-23-34-02-ja Story Transcript:Ja: 冬の朝、伏見稲荷大社は静かに雪に包まれていました。En: On a winter morning, Fushimi Inari Taisha was quietly enveloped in snow.Ja: 無数の朱色の鳥居が、一面の白い雪に映えて、神秘的な光景を作り出していました。En: The countless vermilion torii gates stood out against the expanse of white snow, creating a mystical scene.Ja: この神社の神聖な狐の像は、参拝者と地元の人々にとって大切な存在でした。En: The sacred fox statue of this shrine was an important presence for both worshippers and locals.Ja: しかし、ある朝、狐の像が忽然と姿を消しました。En: However, one morning, the fox statue suddenly disappeared.Ja: 「これは一大事だ…」と神社の管理人である春樹は思いました。En: "This is a major incident..." thought Haruki, the shrine's caretaker.Ja: 狐の像をなくすことは、神社の歴史と神聖さに大きな影響を与えるからです。En: Losing the fox statue would greatly impact the shrine's history and sanctity.Ja: そこで、春樹は地元のジャーナリストであるさくらに相談することにしました。En: So, Haruki decided to consult Sakura, a local journalist.Ja: さくらは、謎の事件を報じることに情熱を注いでいる人物です。En: Sakura is passionate about reporting mysterious events.Ja: 「さくらさん、一緒にこの謎を解いてくれませんか？」春樹は尋ねました。En: "Sakura, could you help solve this mystery with me?" Haruki asked.Ja: さくらは微笑んで答えました。「もちろんです。真相を突き止めるのが私の仕事です。」En: Sakura smiled and replied, "Of course. Getting to the bottom of the truth is my job."Ja: 一方で、神社の関係者たちは、報道が悪影響を及ぼすことを恐れて、協力を渋っていました。En: Meanwhile, the shrine's associates hesitated to cooperate, fearing that the report would have a negative impact.Ja: さらに、絡むように降り続く雪が捜索を困難にしていました。En: Moreover, the continuously falling snow made the search difficult.Ja: しかし、春樹とさくらは諦めませんでした。En: However, Haruki and Sakura did not give up.Ja: 雪嵐が激しくなる中、二人は神社の境内を丹念に調べました。En: As the snowstorm intensified, the two carefully examined the shrine grounds.Ja: そして、遂に新雪の中にかすかに残る足跡を発見しました。En: Finally, they discovered faint footprints left in the fresh snow.Ja: その足跡は、神社の奥にある秘密の部屋へと続いていました。En: These footprints led to a secret room deep in the shrine.Ja: 「ここに何かがあるに違いない！」とさくらが言いました。En: "There must be something here!" said Sakura.Ja: 春樹とともに足跡をたどり、秘密の場所へと進みました。En: Together with Haruki, they followed the footprints and proceeded to the hidden location.Ja: 扉を開けると、そこには失われた狐の像がありました。En: When they opened the door, there was the missing fox statue.Ja: 実は、象が隠されたのは、幸運を求める一人の訪問者の間違いでした。En: In truth, the statue had been hidden due to a visitor mistakenly taking it, thinking it was a lucky charm.Ja: この一件を通じて、春樹は外部の助けを受け入れることが重要であると理解しました。En: Through this incident, Haruki understood the importance of accepting outside help.Ja: そして、さくらは、自分が調べる伝統への深い敬意を持つようになりました。En: Sakura also developed a deep respect for the traditions she investigates.Ja: 神社の神聖さは無事に守られ、事件は円満に解決しました。En: The shrine's sanctity was safely preserved, and the incident was amicably resolved.Ja: 狐の像は、再び雪に彩られた伏見稲荷大社の中で、静かにその神秘的な輝きを放ち続けました。En: The fox statue continued to quietly emit its mysterious glow, once again adorned by the snow at Fushimi Inari Taisha. Vocabulary Words:enveloped: 包まれていましたvermilion: 朱色のmystical: 神秘的なsacred: 神聖なworshippers: 参拝者locals: 地元の人々incident: 一大事caretaker: 管理人sanctity: 神聖さconsult: 相談するpassionate: 情熱を注いでいるmysterious: 謎のhesitated: 渋っていましたcooperate: 協力negative impact: 悪影響continuously: 絡むようにsnowstorm: 雪嵐faint: かすかにfootprints: 足跡storeroom: 秘密の部屋intact: 無事にamicably: 円満にcharm: お守りlucky: 幸運importance: 重要traditions: 伝統intensified: 激しくなるpreserved: 守られsecret: 秘密のmistakenly: 間違い

Sam Nazionale @pranzoakonoha, Silvia Casini"Itadakimasu"Spazio Varesina, Milanofino al 6 aprile 2026http://www.vertigosyndrome.ithttp://www.spaziovaresina204.itDopo il grande successo di Genova, ITADAKIMASU, la mostra immersiva che trasforma i piatti iconici dell'animazione giapponese in esperienze reali, approda a Milano, allo Spazio Varesina 204, fino al 6 aprile 2026. Con un allestimento completamente rinnovato, la mostra conduce il pubblico in un viaggio sensoriale che intreccia immaginazione e tradizione culinaria del Sol Levante, trasformando il cibo dei cartoni animati in un'esperienza da vivere… Ideata e prodotta da Vertigo Syndrome e curata dal food influencer @pranzoakonoha (Sam Nazionale) insieme alla scrittrice Silvia Casini, l'esposizione ha il patrocinio del Municipio 8 di Milano, del Consolato Generale del Giappone a Milano, di AIRG – Associazione Italiana Ristoratori Giapponesi, e invita il pubblico a scoprire come, negli anime, il cibo diventi linguaggio che racconta emozioni, legami e condivisione.  ANIME, CIBO E TRADIZIONE GIAPPONESENel mondo vivo della cucina giapponese Itadakimasu si sviluppa attraverso 9 sale scenografiche, con 16 video-ricette originali, 38 sculture realizzate con la tecnica giapponese dello shokuhin sampuru, 14 stampe ukiyo-e, 22 poster relativi allo Studio Ghibli, 37 poster, 4 cartonati di anime giapponesi e le illustrazioni di Loputyn e Blackbanshee, oltre a contenuti interattivi e a un ricco bookshop tematico.Questa varietà di elementi non è semplice decorazione: ciascun dettaglio trasporta i visitatori nel mondo vivo della cucina giapponese degli anime, immergendoli tra sapori, profumi e storie che hanno conquistato generazioni. Ogni dettaglio accompagna i visitatori dentro la cucina animata, tra sapori, profumi e storie capaci di attraversare generazioni. In Giappone il cibo è un racconto che custodisce memoria e condivisione: un ramen fumante, un onigiri avvolto nell'alga o un bentō colorato riescono a emozionare quanto a far venire l'acquolina in bocca. Itadakimasu è molto più di una mostra.  E' un viaggio sensoriale nel cuore di una delle tradizioni culinarie più raffinate del mondo. Attraverso il linguaggio dell'animazione, con scene tratte da opere dello Studio Ghibli, di Mamoru Hosoda e Makoto Shinkai, ogni piatto animato diventa esperienza da vivere con tutti i sensi. A tutti i visitatori verrà regalato all'ingresso un piccolo ricettario creato appositamente da Sam per questa mostra.  IL PERCORSO ESPOSITIVOLe nove sale raccontate Il Santuario di InariUn inizio sacro e suggestivoAll'ingresso della mostra, i visitatori si troveranno di fronte a Inari, il kami, ovvero la divinità giapponese del raccolto, dell'agricoltura, della fertilità e della prosperità. Qui sarà possibile fare un'offerta simbolica, scegliendo tra una varietà di doni preziosi per il kami. Accanto a Inari, le eleganti volpi – messaggere divine che popolano la cultura nipponica – accompagneranno i visitatori nell'esplorazione del percorso. L'esperienza in sala guiderà il pubblico attraverso la storia della cucina giapponese, illustrando la differenza tra washoku, l'arte culinaria tradizionale, e yōshoku, i piatti occidentali adattati ai gusti giapponesi a partire dall'Epoca Meiji.Gli offerenti saranno chiamati a rievocare un momento di offerta rituale, non solo un ringraziamento ma un'espressione di gratitudine e riconoscenza verso il cibo e la sua linfa vitale. Adesso, il viaggio all'interno della mostra può iniziare! HanamiLa magia della fioritura dei ciliegiNon poteva mancare una sala esperienziale dedicata a uno dei momenti più importanti nella tradizione giapponese: la fioritura dei ciliegi sakura in primavera.Un'esperienza carica di valenze culturali e simboliche, dove si celebra l'armonia della natura e si rende omaggio alla vita e alla memoria di chi ci ha preceduto: un invito a riflettere sulla vita e sulla sua caducità.Attraverso giochi di luci e ombre, i visitatori possono godere di un pic-nic sotto gli alberi, proprio come fanno i giapponesi tra marzo e aprile, oppure contemplare lo sbocciare dei fiori nella loro forma più pura, da soli o in compagnia. Questo ambiente esperienziale chiude il percorso della mostra, invitando tutti a immergersi nella bellezza e nella spiritualità della natura giapponese. La sala dei bentōCome iniziare la giornata in Giappone Ogni mattina, in Giappone, mamme, studenti e lavoratori si alzano presto per preparare il bentō, il tradizionale porta pranzo giapponese. Non si tratta solo di un pasto, ma di un piccolo rito quotidiano: ogni ingrediente viene scelto con cura e disposto in maniera estetica e funzionale, dal riso alle polpette, dal tamagoyaki ai fritti di carne o pesce. La mostra ricostruisce una cucina tipica giapponese, dal gusto retrò, mostrando le diverse varianti del bentō: quelli per bambini, decorati con forme di animali o creature kawaii, e quelli ispirati ai grandi film d'animazione, come Il mio vicino Totoro di Hayao Miyazaki o Suzume di Makoto Shinkai. Grazie a tutorial pratici, i visitatori possono scoprire come realizzare le celebri polpette di riso onigiri, i “tako-wurstel” a forma di polpo e le Bunny Apples, mele intagliate a forma di coniglio.E non mancano i trucchi delle mamme giapponesi per trasformare anche una semplice omelette in un piccolo capolavoro visivo e gustativo. La Sala RāmenTra gusto e tradizione Pur avendo origini cinesi, il rāmen è oggi uno dei piatti più rappresentativi della cultura giapponese contemporanea e il primo ad aver conquistato l'Occidente grazie agli anime, in particolare Naruto di Masashi Kishimoto. La sala ricrea un rāmen bar ispirato ai locali tradizionali giapponesi, con una lunga schiera di postazioni in legno individuali che separano i clienti, permettendo  di gustare la pietanza in una piccola dimensione intima ma accogliente. L'esposizione racconta anche la ricchezza del mondo del rāmen, con oltre duecento varianti ufficialmente codificate in Giappone, nate da quattro tipologie principali e arricchite dall'influenza delle cucine regionali e stagionali dell'arcipelago. Il Banchetto dei KamiIl cibo come rito e simbolo Ispirata a La città incantata di Hayao Miyazaki, questa sala rende omaggio al legame profondo tra cibo, cultura e spiritualità giapponese. Al centro, il tavolo del banchetto offre una straordinaria varietà di piatti tradizionali, ciascuno scelto non solo per la bellezza visiva, ma anche per il significato simbolico che porta con sé. Ogni pietanza rappresenta un frammento della cultura nipponica, unendo estetica e tradizione in un'esperienza che parla tanto al corpo quanto allo spirito. Le riproduzioni dei piatti, realizzate con la tecnica giapponese dello shokuhin sampuru, permettono di osservare da vicino colori, forme e dettagli che rendono ogni portata un piccolo capolavoro.Questa sala permette ai visitatori di immergersi nel mondo degli anime e della cucina giapponese, scoprendo come il cibo possa diventare un ponte tra storia, leggende e legami culturali, celebrando la ricchezza del patrimonio culinario del Sol Levante. L'estate giappnese e i grandi MatsuriColori, sapori e tradizioni Non sarebbe il Giappone senza le grandi feste estive, che trasformano le città in esplosioni di colori, suoni e profumi. La sala dedicata a Tanabata permette ai visitatori di immergersi in questa atmosfera unica, ricreando le tipiche bancarelle di street food con tutte le prelibatezze che rendono questi festival indimenticabili: takoyaki, polpette di polpo simbolo di Osaka, korokke, crocchette di patate e carne, granite kakigori dai colori vivaci, taiyaki e i temarizushi tipici della festa. I tanzaku (piccole strisce di carta washi colorata a cui i giapponesi affidano i loro desideri) e le decorazioni tradizionali completano l'allestimento.Gli stessi visitatori potranno scrivere un Tanzaku con il proprio desiderio e appenderlo al bambù per Orihime, la Principessa Tessitrice protagonista della magica notte di Tanabata. Il CafèDolcezze, bevande e atmosfere kawaii Chiunque visiti il Giappone resta subito colpito dalla creatività e dalla varietà dei suoi café, locali curatissimi e spesso tematici, dove è possibile gustare bevande coloratissime, dolci, soft drinks e talvolta anche piatti caldi.La sala ricrea l'esperienza di un autentico café giapponese, ispirato a locali iconici come i Maid Cafè, Butler Cafè e Neko Cafè, ma anche a spazi dedicati a colori, animali o eventi temporanei. Icone dell'animazione come Sailor Moon e Creamy trovano qui il loro ambiente naturale: riproduzioni in tecnica shokuhin sampuru, gadget originali e contenuti video interattivi permettono ai visitatori di immergersi completamente nella cultura del cafè giapponese, tra dolcezza, estetica e divertimento. Il Natale giapponeseTradizione occidentale e gusto locale La sala dedicata al Natale mostra come le festività occidentali siano state reinterpretate in Giappone, con colori, oggetti e allestimenti tipici. Anche negli anime, il Natale diventa momento di condivisione e scoperta culinaria: i personaggi consumano i peculiari piatti pop associati alla festa, mostrando quanto ilcibo sia centrale anche quando non è strettamente “tradizionale”. Qui i visitatori scoprono due piatti simbolo della stagione: il Kentucky Fried Chicken, reso popolare in Giappone da una celebre campagna pubblicitaria negli anni '70, e la ChDiventa un supporter di questo podcast: https://www.spreaker.com/podcast/il-posto-delle-parole--1487855/support.IL POSTO DELLE PAROLEascoltare fa pensarehttps://ilpostodelleparole.it/

Dave talks to a true multi-hyphenate, the political adviser, author, and, of course, chef Sam Kass. They talk about how he found his way into cooking for the Obama family at the White House (7:05), the dangers of our current food consumption (21:45), and what changes consumers and our government can, and have to, make to keep our favorite foods and food systems alive. After the interview, Dave answers an Ask Dave on homemade condiments (1:02:30) before finishing Part 2 of his ramen cooking, creating the broths and tares, and bringing it all together with the noodles from the cooking segment in Ruby Tandoh's episode (1:08:12). He serves his completed, and delicious, ramen to some special guests. Get your copy of Sam's book 'The Last Supper': https://bookshop.org/p/books/the-last-supper-how-to-overcome-the-future-food-crisis-sam-kass/7c6d969635265644. Learn more about Acre Venture Partners: https://acre.vc/. Learn more about Avec: https://www.avecrestaurant.com/. Learn more about Michelle Obama's Let's Move campaign: https://letsmove.obamawhitehouse.archives.gov/. Learn more about SHIA: https://shiarestaurant.org/?. Learn more about Blue Hill at Stone Barns: https://www.bluehillfarm.com/. Learn more about Inari: https://inari.com/. Learn more about Asahikawa Ramen Aoba: https://www5b.biglobe.ne.jp/~aoba1948/. Learn more about Benton's: https://www.bentonscountryham.com/. Learn more about Mugaritz: https://www.mugaritz.com/en/. Learn more about Café Boulud: https://cafeboulud.com/nyc/. Learn more about Pizzeria Bianco: https://www.pizzeriabianco.com/. Send in your Ask Dave questions to bit.ly/AskDaveForm or askdave@majordomomedia.com. Subscribe to the show on YouTube: https://www.youtube.com/@thedavechangshow. Subscribe to Recipe Club on YouTube: https://www.youtube.com/@recipeclubofficial. Submit your favorite food moments in your favorite movies to majorfoodporn.com. Join our community Discord on majordomo.com. Try Claude for free today at Claude.ai/DaveChang. Host: Dave Chang Guest: Sam Kass Majordomo Media Producer: David Meyer Majordomo Media Coordinator: Molly O'Keeffe  Spotify Producer: Felipe Guilhermino Editor: Stefano Sanchez Learn more about your ad choices. Visit podcastchoices.com/adchoices

Au-delà du cercle Arctique, dans les régions septentrionales de Suède, Norvège, Finlande ou de Russie vit le dernier peuple autochtone d'Europe : les Sámis. Voyage en Finlande au cœur du Sápmi, la terre de leurs ancêtres… Répartis sur un vaste territoire, longtemps dénué de frontières, les Sámis sont aujourd'hui 80 000 habitants environ. Pendant des milliers d'années, les Sámis ont vécu nomades, de la pêche et de la chasse, au gré des transhumances de leurs troupeaux de rennes, cultivant un mode de vie pacifique, en harmonie avec le monde vivant, à la source de leur cosmogonie. Dans les langues sámies, il n'y a aucun mot pour dire « haine » mais il en existe plus de 300 pour décrire la neige. Oubliez le terme « Laponie » ou « Lapons », des exonymes coloniaux péjoratifs, qui en suédois les désignent comme des « porteurs de haillons ». Des siècles de colonisation et d'assimilation ont certes mis à mal l'identité culturelle, artistique et linguistique du peuple sámi; mais depuis 1986, il bénéficie d'une reconnaissance officielle ; il a son drapeau, un Parlement sámi en Norvège, en Suède, et en Finlande depuis 1996. Et c'est justement en Finlande, qu'est partie Jeanne Lacaille, à la rencontre de celles et ceux qui œuvrent pour faire entendre la voix des Sámis, aujourd'hui encore confrontés à de nombreuses menaces : prédations foncières liées à l'extension de l'agriculture ou le développement de projets miniers ou éoliens sur leurs terres, racisme, surtourisme et bien sûr, changement climatique, la zone arctique se réchauffant quatre fois plus vite que le reste de la planète.  Longtemps écartés des réflexions stratégiques et des décisions politiques concernant leur territoire, les Sámis luttent depuis plus de cinquante ans pour une reconnaissance politique, reconquérir leurs droits, leur identité et leur dignité, et surtout préserver leur terre. Aujourd'hui, toute une jeune génération d'activistes sámis prend le relais des aînés, sur fond de joik, cette tradition chantée sámie parmi les plus anciennes d'Europe, qui résonne particulièrement dans les immensités de la toundra.  Un voyage sonore en deux épisodes de Jeanne Lacaille, initialement diffusé en avril 2025. Avec : Teija Kaartokallio, présidente de l'association Suoma Sámi Nuorat Taija Aikio, conservatrice de Siida, le musée sámi d'Inari Mikkâl Antti Morottaja alias Amoc, journaliste à Yle Sami Radio et rappeur Anna Näkkäläjärvi-Länsman alias Ánnámáret, musicienne, chanteuse de joiks et éleveuse de rennes Asko Länsman, éleveur de rennes et mari d'Anna Niila-Juhán Valkeapää, secrétaire de l'association Suoma Sámi Nuorat et président du comité des jeunes sámis du Parlement Sámi de Finlande  Tuomas Aslak Juuso, second vice-président du Parlement Sámi de Finlande et éleveur de rennes Áslak Holmberg, membre actif de la communauté et ancien président du Conseil Sámi. En savoir plus : sur le Musée Siida, musée sámi et centre pour la nature d'Inari sur le Conseil Sámi ou Saami Council, une ONG créée en 1956 pour la défense du peuple sámi et composée de membres de Finlande, Suède, Norvège et Russie sur le Parlement Sámi en Finlande qui se réunit au Centre culturel sámi Sajos à Inari sur Suoma Sámi Nuorat, l'association des jeunes Sámis de Finlande  sur la musique d'Ánnámáret, musicienne et joikeuse sámie sur le rappeur sámi Amoc, son instagram : @amocofficial sur Yle Sámi Radio, la radio des Sámis en Finlande sur le Festival Ijahis Idja organisé par Ánnámáret, qui se tient chaque année, en août, à Inari. Programmation musicale : Amoc & Ailu Valle, Suola ja nuaidi 2025 Ánnámáret, Heaikka Iŋger Ánná 2025

Today in Lighting is brought to you by MaxLite, energy-efficient products for over 30 years. Learn more. Highlights today include: San'an and Inari to Acquire Lumileds, Legrand's Strong First-Half 2025 Results, Dialight will Officially Inaugurate Its New Malaysia Manufacturing Facility, DarkSky Lighting Brings Life to Cathedral Gardens.

This week on MYTH, we're headed to Japan for a look at the duality of foxes.  You'll learn that you should never make bets while drunk, that nothing good happens on a moor, and that tricks are less tricky when you expect them. Then, in Gods and Monsters, there's no telling just how much a single act of kindness can change things. Source: Japanese Folklore

In this episode of Supernatural Japan, we explore the mysterious world of the Kitsune, Japan's legendary fox spirit. Discover how these shape-shifting creatures bridge the gap between myth and reality—revered as protectors, feared as tricksters, and closely linked to the Shinto deity Inari. We dive into the history, folklore, and modern-day sightings of Kitsune, as well as the cultural significance of the real-life fox in Japan. Whether you're a fan of Japanese mythology, the supernatural, or hidden cultural gems, this episode offers a captivating journey into one of Japan's most iconic and enchanting legends.Support the podcast (Help fund the creation of new episodes):https://buymeacoffee.com/busankevinFollow the podcast: Instagram: https://www.instagram.com/supernaturaljapanBluesky: https://bsky.app/profile/madformaple.bsky.socialX: https://x.com/MadForMapleFacebook: https://www.facebook.com/groups/supernaturaljapanEmail: supernaturaljapan@gmail.com YouTube: https://www.youtube.com/@BusanKevinNEW podcast companion blogs! https://justjapanstuff.com/Website: https://supernaturaljapan.buzzsprout.comSupport the show

Land Acknowledgement: Pacific Sámi Searvi is headquartered in what is now known as Seattle, Washington, which is on the unceded land of the Duwamish People. This episode was recorded in Seattle, and in Sápmi, the homeland of the Sámi people.In this episode, we talk with Annika Pasanen, a sociolinguist, professor, and longtime language activist based in Inari, Finland. We explore what language revitalization really takes, what language means for identity and belonging, who can and should speak Sámi, and where Sámi languages may be headed in the future.Pacific Sámi Searvi was created to bring together people in the diaspora, embracing Sámi culture and community. Our mission is to honor, cultivate, and expand understanding of Sámi culture, heritage, and contemporary issues.Ollu giitu – a special thank you to our featured Sámi artists: Iŋgor Ántte Áilu Gaup (Áilloš), Ville Söderbaum, and Hildá Länsman.Learn more at www.pacificsami.org or email us at pacificsamisearvi@gmail.com.

Fluent Fiction - Japanese: Blossoms and Shutters: Capturing Time at Fushimi Inari Find the full episode transcript, vocabulary words, and more:fluentfiction.com/ja/episode/2025-04-21-22-34-02-ja Story Transcript:Ja: 春の日差しが降り注ぎ、伏見稲荷大社は桜の花びらで華やかさを増していた。En: The spring sunlight poured down as Fushimi Inari Taisha became even more vibrant with cherry blossom petals.Ja: 赤い鳥居が連なる山道を人々が行き交う。En: People came and went along the mountain path lined with red torii.Ja: 桜まつりの音と香りが、境内を賑わわせている。En: The sounds and scents of the cherry blossom festival enlivened the shrine grounds.Ja: ユイは大学生で、写真が大好きだ。En: Yui was a university student who loved photography.Ja: 彼女の弟、タケシは冒険心に満ちていて、いつも元気だ。En: Her younger brother, Takeshi, was full of adventure and always energetic.Ja: 彼らの親友ハルカは内省的で、物思いにふけるのが好きだった。En: Their close friend Haruka was introspective and enjoyed contemplating things.Ja: 今年の桜まつりで、ユイは完璧な写真を撮りたかった。En: At this year's cherry blossom festival, Yui wanted to take the perfect photo.Ja: 彼女のポートフォリオを完成させるためには、この祭りの決定的な瞬間を捉える必要がある。En: To complete her portfolio, she needed to capture a decisive moment of the festival.Ja: しかし、人込みと変わりやすい天気がその計画を妨げていた。En: However, the crowds and the changeable weather were hindering her plans.Ja: 「山の上に登れば、日没の景色をうまく撮れるかもしれない」とユイは考えた。En: "If I climb to the top of the mountain, I might be able to capture the sunset well," Yui thought.Ja: 彼女は雨が降り始める中、意を決してさらに高く登ることにした。En: She decided to climb higher, even as it began to rain.Ja: 雨が次第に小降りになり、いつの間にか止まった時、太陽はちょうど山陰に沈みかけていた。En: When the rain gradually lessened and eventually stopped, the sun was just about to set behind the mountain.Ja: ユイは瞬間を逃さず、カメラのシャッターを切った。En: Yui didn't miss the moment and snapped the camera shutter.Ja: タケシとハルカは満開の桜の前で笑顔を見せ、その背後には祭りの灯が輝いていた。En: Takeshi and Haruka smiled in front of the fully bloomed cherry blossoms, with the festival lights shining in the background.Ja: その瞬間、ユイは何かを悟った。En: At that moment, Yui realized something important.Ja: 写真を撮るという結果だけでなく、その経験そのものを楽しむことが大切なのだと。En: It wasn't just about the result of taking photos, but enjoying the experience itself was what's valuable.Ja: 彼女は今ここにいること、友達と共有する時間を大切にする新しい価値観を心に刻んだ。En: She engraved a new value in her heart: cherishing being present and the time shared with friends.Ja: 写真は彼女の思っていた以上に素晴らしい出来栄えだった。En: The photo turned out even more amazing than Yui had imagined.Ja: しかし、それ以上にユイは自分がこの瞬間を楽しめたことに幸せを感じていた。En: However, more than that, she felt happiness in being able to enjoy the moment.Ja: そして、これからはあらゆる瞬間を大切にしようと決意するのだった。En: And she resolved to cherish every moment from now on.Ja: 人々は山を下り、祭りの灯がどこまでも続いていた。En: People descended the mountain, with the festival lights continuing endlessly.Ja: ユイ、タケシ、ハルカは日常に戻るが、彼らはこの思い出を胸に抱き続けるに違いない。En: Yui, Takeshi, and Haruka returned to their everyday lives, but they would undoubtedly continue to carry this memory in their hearts. Vocabulary Words:sunlight: 日差しpoured: 降り注ぎvibrant: 華やかさblossom: 花びらenlivened: 賑わわせているintrospective: 内省的contemplating: 物思いにふけるdecisive: 決定的なchangeable: 変わりやすいhindered: 妨げていたgradually: 次第にlessened: 小降りengaged: 意を決してengraved: 刻んだcherishing: 大切にするundoubtedly: 違いない

Au-delà du cercle Arctique, dans les régions septentrionales de Suède, Norvège, Finlande ou de Russie vit le dernier peuple autochtone d'Europe : les Sámis. Voyage en Finlande au cœur du Sápmi, la terre de leurs ancêtres… Répartis sur un vaste territoire, longtemps dénué de frontières, les Sámis sont aujourd'hui 80 000 habitant.e.s environ. Pendant des milliers d'années, les Sámis ont vécu nomades, de la pêche et de la chasse, au gré des transhumances de leurs troupeaux de rennes, cultivant un mode de vie pacifique, en harmonie avec le monde vivant, à la source de leur cosmogonie. Dans les langues sámies, il n'y a aucun mot pour dire «haine» mais il en existe plus de 300 pour décrire la neige… Oubliez le terme «Laponie» ou «Lapons», des exonymes coloniaux péjoratifs, qui en suédois, les désignent comme des «porteurs de haillons». Des siècles de colonisation et d'assimilation ont certes mis à mal l'identité culturelle, artistique et linguistique du peuple sámi; mais depuis 1986, il bénéficie d'une reconnaissance officielle ; il a son drapeau, un Parlement sámi en Norvège, en Suède, et en Finlande depuis 1996.Et c'est justement en Finlande, qu'est partie Jeanne Lacaille, à la rencontre de celles et ceux qui œuvrent pour faire entendre la voix des Sámis, aujourd'hui encore confrontés à de nombreuses menaces : prédations foncières liées à l'extension de l'agriculture ou le développement de projets miniers ou éoliens sur leurs terres,  racisme, surtourisme et bien sûr, changement climatique, la zone arctique se réchauffant quatre fois plus vite que le reste de la planète. Longtemps écartés des réflexions stratégiques et des décisions politiques concernant leur territoire, les Sámis luttent depuis plus de cinquante ans pour une reconnaissance politique, reconquérir leurs droits, leur identité et leur dignité, et surtout préserver leur terre. Aujourd'hui, toute une jeune génération d'activistes sámis prend le relais des aînés, sur fond de joik, cette tradition chantée sámie parmi les plus anciennes d'Europe, qui résonne particulièrement dans les immensités de la toundra. Un voyage sonore en deux épisodes de Jeanne Lacaille.  Avec :- Teija Kaartokallio, présidente de l'association Suoma Sámi Nuorat- Taija Aikio, conservatrice de Siida, le musée sámi d'Inari- Mikkâl Antti Morottaja alias Amoc, journaliste à Yle Sami Radio et rappeur- Anna Näkkäläjärvi-Länsman alias Ánnámáret, musicienne, chanteuse de joiks et éleveuse de rennes- Asko Länsman, éleveur de rennes et mari d'Anna- Niila-Juhán Valkeapää, secrétaire de l'association Suoma Sámi Nuorat et président du comité des jeunes sámis du Parlement Sámi de Finlande - Tuomas Aslak Juuso, second vice-président du Parlement Sámi de Finlande et éleveur de rennes- Áslak Holmberg, membre actif de la communauté et ancien président du Conseil Sámi. En savoir plus :- sur le Musée Siida, musée sámi et centre pour la nature d'Inari- sur le Conseil Sámi ou Saami Council, une ONG créée en 1956 pour la défense du peuple sámi et composée de membres de Finlande, Suède, Norvège et Russie- sur le Parlement Sámi en Finlande qui se réunit au Centre culturel sámi Sajos à Inari- sur Suoma Sámi Nuorat, l'association des jeunes Sámis de Finlande - sur la musique d'Ánnámáret, musicienne et joikeuse sámie- sur le rappeur sámi Amoc, son instagram : @amocofficial- sur Yle Sámi Radio, la radio des Sámis en Finlande- sur le Festival Ijahis Idja organisé par Ánnámáret, qui se tient chaque année, en août, à Inari.

Gene editing in plants – it's been heralded as the next step-function change in the advancement of agriculture. One Indiana company is advancing the technology fresh off a $144 million venture capital raise. Claudia Nari, Chief Product Officer of Inari, joins today to talk through this historic time for gene editing and biotechnology at large. They get into: From speed to precision, Claudia lays out the differentiation of gene editing to other types of plant breeding Crops of focus for Inari right now and stresses they're focused on to enable farmer success The company's recent venture capital raise, their value proposition and educating investors Inari's unique advantage (knowing what to do, having the tools to do it and being able to do those at the same time) The status of field trials and what commercialization will look like for Inari Biggest problems in-field to be solved through gene editing – from yield to resource efficiencies Regulatory hurdles and Claudia's perspective on the acceptance of gene editing as a technology When will Inari technology be in customer fields? And what's next?

Gene editing in plants – it's been heralded as the next step-function change in the advancement of agriculture. One Indiana company is advancing the technology fresh off a $144 million venture capital raise. Claudia Nari, Chief Product Officer of Inari, joins today to talk through this historic time for gene editing and biotechnology at large. They get into:  From speed to precision, Claudia lays out the differentiation of gene editing to other types of plant breeding Crops of focus for Inari right now and stresses they're focused on to enable farmer success The company's recent venture capital raise, their value proposition and educating investors Inari's unique advantage (knowing what to do, having the tools to do it and being able to do those at the same time) The status of field trials and what commercialization will look like for Inari Biggest problems in-field to be solved through gene editing – from yield to resource efficiencies Regulatory hurdles and Claudia's perspective on the acceptance of gene editing as a technology When will Inari technology be in customer fields? And what's next? 

Inari Agriculture is working to solve the critical issues of food security and sustainability through AI-powered predictive design and advanced multiplex gene editing, creating seeds that maximize yield while minimizing environmental impact.

In this episode of the DeviceTalks Weekly Podcast, we'll play the interview Host Tom Salemi conducted with Adam Elsesser, CEO of Penumbra, which has grown into a force in the vascular and neurovascular industries. Elsesser's path into running a MedTech startup was quite accidental, but that unorthodox path has helped the company develop a unique culture for innovation. Elsesser shares that philosophy in this interview and explains why he prefers uncertainty over risk. Kicking off the episode Jim Hammerand, managing editor of Medical Design and Outsourcing, visits with Chris Newmarker and Salemi to share the highlights of the magazine's leadership issue including an in-depth interview he did with former Edwards Lifesciences CEO Mike Mussallem. The three then run through this week's Newmarker's Newsmakers - Integra, Olympus, Johnson & Johnson, Boston Scientific, Stryker, and Inari. Go to DeviceTalks.com to register for our conferences and digital events. Thanks for listening to this episode of the DeviceTalks Weekly Podcast. Subscribe to the DeviceTalks Podcast Network so you don't miss a future episode.

Joe's Premium Subscription: www.standardgrain.comGrain Markets and Other Stuff Links-Apple PodcastsSpotifyTikTokYouTubeFutures and options trading involves risk of loss and is not suitable for everyone.0:00 Re-Inflation and Grain Prices4:15 Argentina7:46 Farmer Sentiment9:29 Ethanol Exports Spike11:12 Ag Startup Valuation12:11 Corn FlashStock Market Tumbles Amid Inflation ConcernsThe stock market took a hit on Tuesday with the Dow Jones dropping 0.4%, the S&P 500 declining 1.1%, and the Nasdaq falling 1.9%. The continued resilience of the economy has pushed back expectations for when the Federal Reserve will begin cutting interest rates this year. Additionally, concerns are rising that President-elect Donald Trump's tariff plans could lead to inflationary pressures.USDA Optimistic About Argentina's Soybean CropUSDA's Argentina office is maintaining a positive outlook for the country's soybean crop. The crop forecast remains steady at 52 million metric tons (mmt), with an increase in soybean acres and ideal growing conditions contributing to this stable projection. La Niña conditions may pose a risk to yields, but record-high soybean crush of 42 mmt is expected, driven by strong exports and consistent crush rates. US Farmer Sentiment Declines Slightly in DecemberUS farmer sentiment dropped slightly in December, with the Purdue CME Group Ag Economy Barometer Index falling to 136, a 9-point decline from November. Despite this, the index remains at its highest level since August 2021. The slight dip is attributed to farmers' concerns about farm conditions and the agriculture industry, but they remain optimistic about the future, particularly after the presidential election. The potential for a trade war under Trump's administration is a rising concern, with 48% of farmers now believing a trade war is either likely or very likely, up from 42% in November.US Ethanol Exports Surge in NovemberUS ethanol exports saw a major boost in November, climbing to 187.6 million gallons, a 31% increase from October. 2024 exports are on track to surpass 1.9 billion gallons, which would represent 12% of US ethanol production and set a new record. The surge is largely driven by strong growth in key markets like Canada, India, and the European Union. While exports of dried distillers grains fell 15% in November, they were still 14% higher than the same time last year.Inari Agriculture's Valuation SoarsInari Agriculture, an agtech startup, has seen its valuation skyrocket in 2024. The company raised $144 million in new funding, increasing its valuation by 32% to $2.17 billion. Inari develops wheat, corn, and soybeans that require less fertilizer, water, and land, providing sustainable solutions for farmers. The additional funding will help Inari expand its innovative solutions and strengthen its position in the agriculture tech space.USDA Reports Flash Sale of CornThe USDA reported a flash sale of 110,000 metric tons (4 million bushels) of corn to Colombia for delivery during the 2024/2025 marketing year.

Erfahre hier mehr über unseren Partner Scalable Capital - dem Broker mit Flatrate und Zinsen. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Aktien + Whatsapp = Hier anmelden. Lieber als Newsletter? Geht auch. Das Buch zum Podcast? Jetzt lesen. Meta macht auf X.com & stampft Fact-Checking ein. TaskUs leidet. Trump, Dana White & Musk freut's. Freude gab's ansonsten durch Übernahmen bei Getty & Shutterstock, Stryker & Inari, Cintas & UniFirst. Außerdem hilft Moderna gegen Vogelgrippe & Volvo läuft. KION, Aurora & Micron haben gestern dank NVIDIA-Rückenwind zugelegt. Nur NVIDIA (WKN: 918422) hat vom Rückenwind nix gemerkt. Denn Innovation allein bringt noch kein Geld. Alle schauen auf die Leitzinsen der FED und EZB. Aber: Gut Ding braucht Weile und auch China ist einen Blick wert. Was Aktionäre sonst noch über Zinsen wissen müssen, haben wir mit Christian Röhl besprochen - dem Chief Economist von Scalable Capital. Diesen Podcast vom 08.01.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

We're wandering around the busy streets in Kyoto for the first time together and while we still recommend Kyoto despite its overtourism crowd, there are some places we still recommend avoiding here. (especially with toddlers)Enjoy the outdoor Kyoto ambiance for this episode.Check us out on:www.tkorajio.com***Support our Patreon to get access to bonus episodes and episodes 1-50 over at:https://www.patreon.com/TKOrajioPlease give us a 5 star review on Spotify and Apple Podcast to help us out Contact us at:tkorajio@gmail.comInstagram: tko_rajioTwitter @TKO_RAJIO

In this compelling episode of The Life of Flow Podcast, host Miguel is joined by Shon Chakrabarti MD MPH, CMO of Limflow, Michael Siah, Director of Limb Salvage at UT Southwestern Medical Center, and Lucas. Together, they explore the groundbreaking acquisition of Limflow by Inari and its potential to revolutionize the treatment landscape for CLTI patients. Through dynamic discussion and candid reflections, the group unpacks the clinical, technical, and business implications of this strategic merger, highlighting its impact on patient outcomes, institutional approaches, and the future of endovascular therapies.Key Topics Covered:Understanding the Inari-Limflow Synergy (00:01 - 09:52):Why the acquisition makes sense for unmet patient needs.Strategic alignment with Inari's ethos of purpose-built solutions.Overlaps in vascular innovations and CLTI management.Clinical and Economic Implications of CLTI Therapies (09:53 - 24:04):The importance of vertical integration in hospitals for CLTI programs.Addressing misconceptions about the costs and outcomes of amputations.New reimbursement codes and economic incentives for hospitals.Evolution of DBA Techniques (24:05 - 38:43):The journey of deep vein arterialization from experimental to commercial viability.Insights into procedural advancements, including new access points and technologies.The collaborative WhatsApp group fostering a global exchange of ideas.The Path Forward: Research, Collaboration, and Education (38:44 - 48:24):The role of continued peer-to-peer training and global education in scaling CLTI solutions.Investigator-Initiated Research Programs to address pressing clinical questions.Future product developments and their potential to expand patient reach.What Lies Ahead for CLTI Therapies (48:25 - End):Predicting the evolution of the field over the next 5-10 years.Controversial yet thought-provoking ideas about preemptive applications of DBA.Reflections on patient outcomes and the transformative impact of new therapies.Memorable Quotes:“Inari and Limflow are united by a commitment to tackling large unmet patient needs with purpose-built solutions.” – Shon Chakrabarti“Even when DBA patency declines, patients often end up better off than when they started—this is a game changer.” – MiguelConnect with Us:Miguel – https://www.linkedin.com/in/miguel-montero-baker-a44354214/Lucas – https://www.linkedin.com/in/lucasferrermdGuests:Shon Chakrabarti – https://www.linkedin.com/in/shon-chakrabarti-md-mph-018a7394/Michael Siah – https://www.linkedin.com/in/michael-siah-965585b1/Stay tuned for future episodes diving deeper into groundbreaking innovations in cardiovascular and endovascular medicine. Don't forget to subscribe, leave a review, and share this episode with colleagues passionate about transforming patient care!

Welcome back, Alchemists!! This week we talk through our magical/paranormal experience at the Inari shrine in Kyoto on our last TrovaTrip. Links mentioned: Iceland TrovaTrip with Emily & KristaLyn (2 spots left!): ⁠https://trovatrip.com/trip/europe/iceland/iceland-with-emily-dexter-jun-2025⁠⁠  Sacred Spaces Gathering: https://www.sacredspacesgathering.com/  KristaLyn's Patreon: https://www.patreon.com/modernschoolofancientwisdom Emily's Patreon: https://patreon.com/likerofwords Connect with Emily & KristaLyn: Follow Emily on TikTok + Instagram @likerofwords Follow KristaLyn on TikTok + Instagram @kristalynsofia

Season 3 continues with Nation Building heart throb , Okuninushi

Sailor Noob is the podcast where a Sailor Moon superfan and a total noob go episode by episode through the original Sailor Moon series!The Sailor Senshi are trapped in Nehellenia's realm this week as Usagi falls under a mysterious and forgetful curse. Can her friends save her in time to rescue Mamoru from eternal servitude to the Dark Queen?In this episode, we discuss kitsune yokai, foxfire, Inari, kitsune nybob or "fox wife", kitsune gao or "fox face", kitsune possession, hoshi no tama or "star balls", and kitsune weddings. We also talk about yuriing on your own time, liking WILLOW, the shojo equivalent of shooting someone in the face, class action suits, DaiCon shenanigans, "Can Minako talk?", stoner torments, ESP DSL esq., letting your dangos down, sailor slacks, getting rid of "to be", reverse furries, magical boy creatures, and PG-13 foxes!Even naughty foxes can achieve enlightenmentWe're on iTunes and your listening platform of choice! Please subscribe and give us a rating and a review! Arigato gozaimasu!https://podcasts.apple.com/us/podcast/sailor-noob/id1486204787Answer this week's show question on Spotify!Become a patron of the show and get access to our live-action PGSM, Animedification, Utena, and Evangelion podcasts!http://www.patreon.com/sailornoobPut Sailor Noob merch on your body!http://justenoughtrope.threadless.comSailor Noob is a part of the Just Enough Trope podcast network. Check out our other shows about your favorite pop culture topics and join our Discord!http://www.twitter.com/noob_sailorhttp://www.justenoughtrope.comhttp://www.instagram.com/noob_sailorhttps://discord.gg/49bzqdpBpxBuy us a Kōhī on Ko-Fi!https://ko-fi.com/justenoughtrope